Pharmaceutical for treating or preventing chemotherapy-induced peripheral neuropathy
Patent Information
- Application Number
- MYPI2025005007
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-30
- Filing Date
- 2024-02-21
- Publication Date
- 2024-08-24
AI Technical Summary
Current treatments for chemotherapy-induced peripheral neuropathy are inadequate, with few effective options available, leading to significant discomfort and disability that can hinder cancer treatment and improve quality of life for patients.
A pharmaceutical composition containing an alkalinizing agent, such as sodium citrate or potassium citrate, is developed to treat or prevent peripheral neuropathy induced by chemotherapy drugs, which can be administered alone or in combination with cancer chemotherapeutic agents to suppress neuropathy symptoms.
The composition effectively alleviates pain, sensory, and autonomic symptoms associated with chemotherapy-induced peripheral neuropathy, allowing for continued cancer treatment and improved patient quality of life by reducing neuropathy development and severity.
Smart Images

Figure PI2025005007_DRAWING_001 
Figure PI2025005007_DRAWING_002 
Figure PI2025005007_DRAWING_003
Abstract
Description
Medicine for treating or preventing chemotherapy-induced peripheral neuropathy
[0001] The present invention relates to a novel pharmaceutical composition comprising an alkalizing agent. More specifically, the present invention relates to a pharmaceutical composition comprising an alkalizing agent for treating or preventing peripheral neuropathy induced by a chemotherapy drug. This application claims priority to Japanese Patent Application No. 2023-027461 filed in Japan on February 24, 2023, and Japanese Patent Application No. 2023-185444 filed in Japan on October 30, 2023, the contents of which are incorporated herein by reference.
[0002] Cancer chemotherapy can cause, for example, hypoesthesia or dysesthesia in the limbs. These symptoms are caused by peripheral neuropathy and tend to be more severe in the more peripheral parts of the limbs. The symptoms of anticancer drug-induced peripheral neuropathy (sometimes abbreviated as CIPN herein) can interfere with daily life due to unpleasant abnormal sensations, and in severe cases, can make it impossible to walk or put on or take off clothes. CIPN is rarely a transient condition that quickly resolves upon discontinuation of anticancer drugs; improvement can take months or even years, and it is not uncommon for some form of disability to remain for the rest of one's life.
[0003] Although CIPN has long been known as an adverse event, its detailed mechanism remains largely unknown, and no effective treatment has yet been established. Various drugs have been used for treatment, but these have not been sufficiently effective. CIPN is a significant adverse event that hinders the continuation of cancer chemotherapy. Its prevention and treatment could contribute not only to improving the outcomes of cancer treatment but also to improving patients' quality of life. However, the only effective treatment is to discontinue the chemotherapy agent that causes CIPN (Non-Patent Document 1).
[0004] Symptomatic classification of CIPN includes sensory neuropathy, motor neuropathy (numbness), tingling, or pain. Intense pain is also sometimes described as shooting pain or burning pain. Regarding the relationship between these, motor neuropathy and tingling do not necessarily mean intense pain, but it has been reported that almost all patients who experience intense pain also experience motor neuropathy or tingling. The motor neuropathy of CIPN manifests as muscle atrophy and weakness, or flaccid paralysis, predominantly in the distal limbs. Furthermore, tendon reflexes in the limbs are reduced or absent, becoming more pronounced the more distal the limbs are. The autonomic neuropathy of CIPN causes disorders of blood pressure, intestinal motility, or involuntary muscle function, and symptoms may include urinary dysfunction, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus.
[0005] Calcium or magnesium may be administered to prevent CIPN in the hopes of preventing neurotoxicity, but clear evidence of their effectiveness has not been obtained. Medications for numbness or pain include Goshajinkigan, vitamin B12 preparations, nonsteroidal anti-inflammatory drugs, pregabalin, gabapentin, and opioids, but the efficacy of none of these drugs is clear, and there is insufficient evidence to recommend their administration (Non-Patent Document 1). The only medication for which moderate evidence of its effectiveness has been obtained in the guidelines is duloxetine (Non-Patent Document 2). However, it is known that duloxetine often leads to early discontinuation due to adverse events after administration (Non-Patent Document 3).
[0006] On the other hand, some citric acid preparations or alkalizing agents such as sodium bicarbonate are known to be effective for hyperuricemia and gout, which are typical lifestyle-related diseases. It is also known that administration of alkalizing agents can suppress the formation of urinary stones by shifting acidic urine to alkaline urine. It is also known that administration of alkalizing agents to early-stage CKD patients can suppress the progression of renal damage and reduce the blood concentration of uremic substances (Patent Documents 1 and 2). Furthermore, citric acid preparations are known to suppress renal fibrosis in diabetic nephropathy (Patent Document 3). However, it is not known that alkalizing agents are effective in preventing or treating chemotherapy-induced peripheral neuropathy.
[0007] International Publication No. WO 2018 / 193648 International Publication No. WO 2018 / 193752 International Publication No. WO 2020 / 080451
[0008] Guidelines for the Management of Peripheral Neuropathy Associated with Cancer Chemotherapy Neuropathic Pain Pharmacotherapy Guidelines (Revised 2nd Edition) Risk Factors for Adverse Events Associated with Duloxetine in Cancer Patients
[0009] One object of the present invention is to provide a pharmaceutical useful for treating or preventing peripheral neuropathy induced by a chemotherapy drug. Another object of the present invention is to provide an anti-cancer combination preparation comprising an alkalizing agent and a cancer chemotherapy drug, in which the onset of peripheral neuropathy is suppressed. Another object of the present invention is to provide an anti-cancer pharmaceutical composition comprising an alkalizing agent and a cancer chemotherapy drug, in which the onset of peripheral neuropathy is suppressed. Another object of the present invention is to provide an anti-cancer pharmaceutical kit comprising an alkalizing agent and a cancer chemotherapy drug, in which the onset of peripheral neuropathy is suppressed. Another object of the present invention is to provide a method for treating or preventing peripheral neuropathy induced by a chemotherapy drug. Another object of the present invention is to provide a method for treating cancer, in which the onset of peripheral neuropathy is suppressed.
[0010] The present inventors have conducted extensive research to achieve the above-mentioned object and have found that a specific alkalizing agent is useful for treating or preventing peripheral neuropathy induced by chemotherapy drugs, thereby completing the present invention.
[0011] That is, the present invention has the following aspects: (1) A pharmaceutical composition for treating or preventing chemotherapeutic drug-induced peripheral neuropathy, comprising an alkalinizing agent. (2) The pharmaceutical composition according to (1), wherein the chemotherapeutic drug-induced peripheral neuropathy is pain, sensory disorder, motor disorder, autonomic neuropathy, or a complication thereof, caused by peripheral neuropathy. (3) The pharmaceutical composition according to (1) or (2), wherein the chemotherapeutic drug-induced peripheral neuropathy is peripheral neuropathic pain. (4) The pharmaceutical composition according to (3), wherein the peripheral neuropathic pain is shooting pain, burning pain, pain (excluding shooting pain and burning pain), or tingling. (5) The pharmaceutical composition according to (1) or (2), wherein the chemotherapeutic drug-induced peripheral neuropathy is sensory disorder caused by peripheral neuropathy. (6) The pharmaceutical composition according to (5), wherein the sensory disorder caused by peripheral neuropathy is hypoesthesia, hyperesthesia, or dysesthesia. (7) The pharmaceutical composition according to (6), wherein the hypersensitivity is allodynia and the dysesthesia is dysesthesia or paresthesia. (8) The pharmaceutical composition according to (1) or (2), wherein the peripheral neuropathy induced by a chemotherapy drug is autonomic neuropathy caused by peripheral neuropathy. (9) The pharmaceutical composition according to (8), wherein the symptoms caused by autonomic neuropathy are dysuria, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus. (10) The pharmaceutical composition according to any one of (1) to (9), wherein the peripheral neuropathy induced by a chemotherapy drug is peripheral neuropathy in which symptoms appear in the limbs.
[0012] (11) The pharmaceutical composition according to any one of (1) to (10), wherein the alkalizing agent is a pharmaceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof. (12) The pharmaceutical composition according to any one of (1) to (11), wherein the alkalizing agent is sodium citrate, potassium citrate, or a hydrate thereof, or a mixture thereof. (13) The pharmaceutical composition according to any one of (1) to (12), wherein the alkalizing agent comprises a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof. (14) The pharmaceutical composition according to any one of (1) to (13), wherein the alkalizing agent is sodium citrate or a hydrate thereof.
[0013] (15) The pharmaceutical composition according to any one of (1) to (14), wherein the pharmaceutical composition is in the form of a tablet. (16) The pharmaceutical composition according to any one of (1) to (10), wherein the alkalinizing agent is sodium bicarbonate. (17) The pharmaceutical composition according to any one of (1) to (16), wherein the chemotherapeutic agent is a cancer chemotherapeutic agent. (18) The pharmaceutical composition according to (17), wherein the cancer chemotherapeutic agent is a cytotoxic anticancer drug, a molecularly targeted anticancer drug, an immunotherapeutic drug, or other anticancer drug. (19) The pharmaceutical composition according to (18), wherein the cytotoxic anticancer drug is at least one anticancer drug selected from the group consisting of paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine. (20) The pharmaceutical composition according to (18), wherein the molecularly targeted anticancer drug is at least one anticancer drug selected from the group consisting of bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, brentuximab vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib. (21) The pharmaceutical composition according to (18), wherein the immunotherapeutic drug is at least one anticancer drug selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab. (22) The pharmaceutical composition according to (18), wherein the other anticancer drug is at least one anticancer drug selected from the group consisting of cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide, and pomalidomide. (23) The pharmaceutical composition according to (17), wherein the cancer chemotherapeutic drug is at least one anticancer drug selected from the group consisting of paclitaxel, vincristine, oxaliplatin, and bortezomib. (24) The pharmaceutical composition according to (23), wherein the cancer chemotherapeutic drug is paclitaxel or oxaliplatin.
[0014] (25) A combined preparation for simultaneous, separate, or sequential administration in the treatment of cancer, the combined preparation comprising at least two separate preparations of an alkalizing agent and a cancer chemotherapeutic drug, and suppressing the onset of peripheral neuropathy. (26) An anti-cancer pharmaceutical composition comprising an alkalizing agent and a cancer chemotherapeutic drug, and suppressing the onset of peripheral neuropathy. (27) An anti-cancer pharmaceutical kit comprising an alkalizing agent in a first compartment and a cancer chemotherapeutic drug in a second compartment, and suppressing the onset of peripheral neuropathy.
[0015] The pharmaceutical composition, combined preparation, and pharmaceutical kit provided by the present invention enable the treatment or prevention of peripheral neuropathy induced by a chemotherapeutic agent, and also enable the treatment of cancer by suppressing peripheral neuropathy induced by a chemotherapeutic agent, particularly a cancer chemotherapeutic agent.
[0016]
[0023] Figure 1 shows the effect of an alkalinizing agent in an oxaliplatin-induced mouse neuropathic pain model, showing the relationship between the number of days since the start of oxaliplatin administration and the pain score for mechanical allodynia and cold dysestesia. Figure 1 shows the effect of an alkalinizing agent in an oxaliplatin-induced mouse neuropathic pain model, showing the pain score for each test group for mechanical allodynia on day 10 from the start of oxaliplatin administration, the pain score for each test group for cold dysestesia on day 3 from the start of oxaliplatin administration, and the body weight of each test group on day 10 from the start of oxaliplatin administration. Figure 2 shows the effect of an alkalinizing agent in a paclitaxel-induced mouse neuropathic pain model, showing the relationship between the number of days since the start of paclitaxel administration and body weight, and the relationship between the number of days since the start of paclitaxel administration and the pain score for mechanical allodynia.
[0023] Figure 1 shows the effect of an alkalizing agent in a paclitaxel-induced mouse neuropathic pain model, showing the pain scores for each test group related to mechanical allodynia on day 14 from the start of paclitaxel administration, and the body weights of each test group on day 14 from the start of paclitaxel administration. Figure 2 shows the effect of an alkalizing agent in a bortezomib-induced mouse neuropathic pain model, showing the relationship between the number of days since the start of bortezomib administration and body weights, and the relationship between the number of days since the start of bortezomib administration and the pain scores related to mechanical allodynia. Figure 3 shows the effect of an alkalizing agent in a bortezomib-induced mouse neuropathic pain model, showing the pain scores for each test group related to mechanical allodynia on day 12 from the start of bortezomib administration, and the body weights of each test group on day 12 from the start of bortezomib administration. 1 shows the effect of an alkalizing agent in a vincristine-induced mouse neuropathic pain model, illustrating the relationship between the number of days since the start of vincristine administration and body weight, and the relationship between the number of days since the start of vincristine administration and the pain score related to mechanical allodynia. 1 shows the effect of an alkalizing agent in a vincristine-induced mouse neuropathic pain model, illustrating the pain score related to mechanical allodynia for each test group on day 14 after the start of vincristine administration, and the body weight for each test group on day 14 after the start of vincristine administration.
[0023] Figure 1 shows the effect of an alkalizing agent in a paclitaxel-induced rat neuropathic pain model, showing the relationship between the number of days since the start of paclitaxel administration and the 50% withdrawal threshold. Figure 2 shows the effect of an alkalizing agent in a paclitaxel-induced mouse neuropathic pain model, showing the pain scores for each test group regarding mechanical allodynia on day 13 after the start of paclitaxel administration. Figure 3 shows the effect of an alkalizing agent in a paclitaxel-induced mouse neuropathic pain model, showing the spontaneous firing frequency per neuron in each test group on day 14 after the start of paclitaxel administration, and the vFF-evoked firing frequency per neuron in each test group on day 14 after the start of paclitaxel administration.
[0023] Figure 1 shows the effect of an alkalizing agent in a paclitaxel-induced mouse neuropathic pain model, showing the spontaneous firing frequency for each individual in each test group on day 14 from the start of paclitaxel administration, and the vFF-induced firing frequency for each individual in each test group on day 14 from the start of paclitaxel administration.
[0024] Figure 1 shows the effect of an alkalizing agent in an oxaliplatin-induced mouse neuropathic pain model, showing the relationship between the number of days since the start of oxaliplatin administration and body weight, and the relationship between the number of days since the start of oxaliplatin administration and the pain score related to mechanical allodynia.
[0025] Figure 1 shows the effect of an alkalizing agent in an oxaliplatin-induced mouse neuropathic pain model, showing the pain score related to mechanical allodynia for each test group on day 10 from the start of oxaliplatin administration, and the body weight for each test group on day 10 from the start of oxaliplatin administration.
[0023] Figure 1 shows the effect of an alkalinizing agent in a paclitaxel-induced mouse neuropathic pain model, showing the relationship between the number of days since the start of paclitaxel administration and body weight, and the relationship between the number of days since the start of paclitaxel administration and the pain score related to mechanical allodynia.
[0024] Figure 1 shows the effect of an alkalinizing agent in a paclitaxel-induced mouse neuropathic pain model, showing the pain score related to mechanical allodynia for each test group on day 14 after the start of paclitaxel administration, and the body weight for each test group on day 14 after the start of paclitaxel administration.
[0017] 1. Pharmaceutical Composition <Pharmaceutical Composition for Treating or Preventing Chemotherapeutic Agent-Induced Peripheral Neuropathy> The pharmaceutical composition for treating or preventing chemotherapeutic agent-induced peripheral neuropathy provided by the present invention may contain an alkalizing agent as an active ingredient. "Containing an alkalizing agent as an active ingredient" means that the alkalizing agent is the main ingredient in the pharmaceutical composition, or that the alkalizing agent functions as a substantial active ingredient for treating or preventing chemotherapeutic agent-induced peripheral neuropathy, and is contained in an effective amount for said treatment or prevention.
[0018] Alkalizing agents are agents that can be used to reduce the HCO3 content of mammalian (especially human) body fluids, such as blood or urine. -An alkalinizing agent is an agent capable of increasing concentration or pH. Examples of alkalinizing agents include pharmaceutically acceptable salts of citric acid, their hydrates, or mixtures thereof, and sodium bicarbonate (baking soda). Examples of pharmaceutically acceptable salts of citric acid include alkali metal citrate salts. Examples of alkali metal citrate salts include potassium citrate and sodium citrate, which may be stable hydrates such as potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O), respectively. Examples of preferred alkalinizing agents contained in the pharmaceutical compositions provided by the present invention include sodium citrate, potassium citrate or its hydrates, or mixtures thereof, such as a mixture of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O). The mixing ratio of potassium citrate monohydrate (C6H5K3O7.H2O) and sodium citrate dihydrate (C6H5Na3O7.2H2O) can be appropriately determined by those skilled in the art. For example, the molar ratio of potassium citrate monohydrate to sodium citrate dihydrate can be 1 part potassium citrate monohydrate to 0.01 to 100 parts sodium citrate dihydrate. The molar ratio of potassium citrate (e.g., potassium citrate monohydrate) to sodium citrate (e.g., sodium citrate dihydrate) can be appropriately determined by those skilled in the art, and may be, for example, 0.85:1.15 to 1.15:0.85, 0.90:1.10 to 1.10:0.90, 0.95:1.05 to 1.05:0.95, or 0.99:1.01 to 1.01:0.99, with 1:1 being preferred.
[0019] Another example of an active ingredient contained in the pharmaceutical composition of the present invention is sodium citrate or a hydrate thereof, such as sodium citrate dihydrate (C6H5Na3O7·2H2O). Another example of an active ingredient contained in the pharmaceutical composition of the present invention is potassium citrate or a hydrate thereof, such as potassium citrate monohydrate (C6H5K3O7·H2O). In one embodiment, the alkalinizing agent contained in the pharmaceutical composition of the present invention may comprise a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof. In one embodiment, the alkalinizing agent contained in the pharmaceutical composition of the present invention may comprise a mixture of sodium citrate or a hydrate thereof and citric acid (e.g., anhydrous citric acid), or a mixture of potassium citrate or a hydrate thereof and citric acid (e.g., anhydrous citric acid). In one embodiment, the alkalinizing agent contained in the pharmaceutical composition of the present invention may be a mixture of potassium citrate or a hydrate thereof, sodium citrate or a hydrate thereof, and citric acid (e.g., anhydrous citric acid). In this case, the mixing ratio (molar ratio) of citric acid (e.g., anhydrous citric acid), potassium citrate, and sodium citrate can be appropriately determined by those skilled in the art and may be, for example, 1:1.7-2.3:1.7-2.3, 1:1.9-2.1:1.9-2.1, or 1:1.95-2.05:1.95-2.05, with 1:2:2 being preferred. In one embodiment, the alkalinizing agent contained in the pharmaceutical composition of the present invention may be a mixture of potassium citrate monohydrate (C6H5K3O7·H2O), sodium citrate dihydrate (C6H5Na3O7·2H2O), and anhydrous citric acid. In this case, the mixing ratio (molar ratio) of anhydrous citric acid, potassium citrate monohydrate (C6H5K3O7.H2O), and sodium citrate dihydrate (C6H5Na3O7.2H2O) can be appropriately set by a person skilled in the art, and may be, for example, 1:1.7-2.3:1.7-2.3, 1:1.9-2.1:1.9-2.1, or 1:1.95-2.05:1.95-2.05, with 1:2:2 being preferred.In one embodiment, the alkalinizing agent contained in the pharmaceutical composition of the present invention may consist solely of a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof. When referring to the weight of citric acid, a pharmaceutically acceptable salt of citric acid, or a hydrate thereof or a mixture thereof (e.g., potassium citrate monohydrate (C6H5K3O7.H2O) and sodium citrate dihydrate (C6H5Na3O7.2H2O)) herein, the weight may be the dry weight.
[0020] In one embodiment, the treatment or prevention of chemotherapy-induced peripheral neuropathy can be treatment or prevention of organic damage to peripheral nerves induced by a chemotherapy drug. In another embodiment, the treatment or prevention of chemotherapy-induced peripheral neuropathy can be treatment or prevention of symptoms caused by chemotherapy-induced peripheral neuropathy, such as pain, sensory disturbance, motor disturbance, autonomic neuropathy, or complications thereof. In one embodiment, the "chemotherapeutic drug-induced peripheral neuropathy" can be pain, sensory disturbance, motor disturbance, autonomic neuropathy, or complications thereof caused by chemotherapy-induced peripheral neuropathy. In another embodiment, the "chemotherapeutic drug-induced peripheral neuropathy" can be chemotherapy-induced peripheral neuropathic pain. In yet another embodiment, the "peripheral neuropathic pain" can be lancinating pain, burning pain, pain (excluding lancinating pain and burning pain), or tingling.
[0021] In one embodiment, the "chemotherapeutic drug-induced peripheral neuropathy" can be a sensory disorder such as hypoesthesia, hyperesthesia, or dysesthesia caused by chemotherapy-induced peripheral neuropathy. The hyperesthesia concept includes allodynia, including mechanical allodynia caused by mechanical stimuli. The dysesthesia concept includes dysesthesia and paresthesia, including cold dysesthesia caused by cold stimuli. One aspect of sensory and / or motor disorders is "numbness." Therefore, the pharmaceutical composition provided by the present invention can be a pharmaceutical composition for treating or preventing numbness caused by chemotherapy-induced peripheral neuropathy.
[0022] In one embodiment, the "chemotherapeutic drug-induced peripheral neuropathy" may be autonomic neuropathy caused by peripheral neuropathy induced by a chemotherapy drug. Typical symptoms caused by the autonomic neuropathy include dysuria, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus. In one embodiment, the "chemotherapeutic drug-induced peripheral neuropathy" may manifest as symptoms in the limbs of mammals (particularly humans), and may particularly manifest as symptoms in the peripheral limbs.
[0023] In one embodiment, chemotherapy-induced peripheral neuropathy can be treated or prevented by administering a pharmaceutical composition comprising an alkalinizing agent as an active ingredient provided by the present invention. In one embodiment, pain, sensory disturbances, motor disturbances, autonomic neuropathy, or complications thereof, caused by chemotherapy-induced peripheral neuropathy can be treated or prevented by administering a pharmaceutical composition comprising an alkalinizing agent as an active ingredient provided by the present invention. Herein, pain caused by peripheral neuropathy may be referred to as peripheral neuropathic pain. The type and severity of chemotherapy-induced peripheral neuropathic pain that can be treated or prevented by the pharmaceutical composition comprising an alkalinizing agent as an active ingredient provided by the present invention are not particularly limited, but typically, pain referred to as shooting pain, burning pain, pain (excluding shooting pain and burning pain), or tingling can be treated or prevented. Herein, sensory disturbances caused by chemotherapy-induced peripheral neuropathy are a concept that encompasses hypoesthesia, hyperesthesia, and dysesthesia. Furthermore, the concept of hyperesthesia includes allodynia, and the concept of dysesthesia includes dysesthesia and paresthesia. Therefore, by administering the pharmaceutical composition provided by the present invention, which contains an alkalizing agent as an active ingredient, sensory disorders such as hypoesthesia, hyperesthesia, and dysesthesia, including allodynia, dysesthesia, and paresthesia, caused by peripheral neuropathy induced by a chemotherapy drug, can be treated or prevented.
[0024] In one embodiment, administration of a pharmaceutical composition provided by the present invention comprising an alkalinizing agent as an active ingredient can treat or prevent symptoms caused by autonomic neuropathy induced by a chemotherapy drug, such as dysuria, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus. In one embodiment, administration of a pharmaceutical composition provided by the present invention comprising an alkalinizing agent as an active ingredient can treat or prevent symptoms occurring in the limbs, particularly symptoms occurring in the peripheral limbs, in mammals (particularly humans).
[0025] As used herein, the term "chemotherapeutic agent" is not particularly limited as long as it can induce peripheral neuropathy, and may be, for example, a "cancer chemotherapeutic agent." Furthermore, the term "cancer chemotherapeutic agent" is not particularly limited as long as it can induce peripheral neuropathy. It is known in the art that the following cancer chemotherapeutic agents tend to induce peripheral neuropathy: cytotoxic anticancer drugs such as paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine. Molecularly targeted anticancer drugs such as bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, brentuximab vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib. Immunotherapeutic drugs such as nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab. Other anticancer drugs such as cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide, and pomalidomide. Here, the terms "cytotoxic anticancer drugs," "molecularly targeted anticancer drugs," "immunotherapeutic drugs," and "other anticancer drugs" are used for convenience in organizing the above-mentioned cancer chemotherapy drugs, and these terms do not limit the species belonging to each class.
[0026] Therefore, as used herein, "peripheral neuropathy induced by a chemotherapy drug" refers to, for example, cytotoxic anticancer drugs such as paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine; bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, and brentuximab. The peripheral neuropathy may be induced by at least one anticancer drug selected from the group consisting of molecularly targeted anticancer drugs such as vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib; immunotherapeutic drugs such as nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab; and other anticancer drugs such as cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide, and pomalidomide. In one embodiment, peripheral neuropathy induced by the above-mentioned cancer chemotherapeutic drugs, i.e., anticancer drugs, can be treated or prevented by administering a pharmaceutical composition provided by the present invention containing an alkalinizing agent as an active ingredient.
[0027] In another embodiment, peripheral neuropathy induced by at least one anticancer drug selected from the group consisting of paclitaxel, vincristine, oxaliplatin, and bortezomib can be treated or prevented by administering a pharmaceutical composition provided by the present invention comprising an alkalinizing agent as an active ingredient. In yet another embodiment, peripheral neuropathy induced by paclitaxel or oxaliplatin can be treated or prevented by administering a pharmaceutical composition provided by the present invention comprising an alkalinizing agent as an active ingredient. In yet another embodiment, peripheral neuropathy induced by bortezomib or vincristine can be treated or prevented by administering a pharmaceutical composition provided by the present invention comprising an alkalinizing agent as an active ingredient.
[0028] As used herein, "treatment" includes eliminating, curing, curing, or remission of "pathological" or "abnormal" symptoms, conditions, or diseases, and actions or means therefor; it also includes "suppressing" the worsening of "pathological" or "abnormal" symptoms, conditions, or diseases, and actions or means therefor; and it is a concept that includes "improvement." In one embodiment, "treatment" refers to eliminating, curing, curing, or remission of "pathological" or "abnormal" symptoms, conditions, or diseases, and actions or means therefor. In another embodiment, "treatment" refers to eliminating, curing, curing, or remission of "pathological" or "abnormal" symptoms, conditions, or diseases. In one embodiment, "treatment" includes administration of a pharmaceutical composition comprising an alkalinizing agent as an active ingredient, provided by the present invention, as part of the cancer chemotherapy drug, i.e., anti-cancer drug, treatment. In one embodiment, "treatment" may include eliminating, curing, curing, or remission of "pathological" or "abnormal" symptoms, conditions, or diseases caused by the administration of a cancer chemotherapeutic drug, i.e., an anticancer drug, by starting administration of a pharmaceutical composition provided by the present invention containing an alkalizing agent as an active ingredient before the administration of the cancer chemotherapeutic drug, i.e., an anticancer drug, and may also include "suppressing" the worsening of "pathological" or "abnormal" symptoms, conditions, or diseases and may also include actions or means for doing so, and may also include the concept of "improvement." In one embodiment, when administration of a pharmaceutical composition provided by the present invention containing an alkalizing agent as an active ingredient is started before the administration of the cancer chemotherapeutic drug, i.e., an anticancer drug, administration may be started 10 days to 1 day, 7 days to 1 day, or 3 days to 1 day before the administration of the cancer chemotherapeutic drug, i.e., an anticancer drug.
[0029] As used herein, "suppression" refers to stopping, slowing, or reducing the worsening or progression of a symptom, condition, or disease, and includes actions or means for doing so, and also refers to improving the symptom, condition, or disease, or includes actions or means for doing so. Here, "improvement" refers to bringing a "pathological" or "abnormal" symptom, condition, or disease closer to a "healthy" or "normal" state, or includes actions or means for doing so, and refers to bringing the condition to a "healthy" or "normal" state, or includes actions or means for doing so. Accordingly, in one embodiment, "improvement" refers to a numerical value that is an indicator of a "pathological" or "abnormal" symptom or condition decreasing or increasing in accordance with the "improvement," approaching a normal value, or becoming a normal value. The "worsening or progression of a symptom, condition, or disease" refers to the worsening or progression of a "pathological" or "abnormal" symptom, condition, or disease, and the worsening or progression from a "healthy" or "normal" state to a "pathological" or "abnormal" symptom, condition, or disease. In one embodiment, "suppression" refers to stopping, slowing, or reducing the worsening or progression of a symptom, condition, or disease, or an act or means therefor. In another embodiment, "suppression" refers to stopping, slowing, or reducing the worsening or progression of a symptom, condition, or disease. As used herein, "healthy" refers to a state free from acute or chronic disease or disorder, and "normal" refers to a state normally experienced by a healthy subject.
[0030] As used herein, "prevention" is a concept that includes preventing the onset of "pathological" or "abnormal" symptoms, conditions, or diseases, and actions or means for achieving this. Therefore, "suppressing" "pathological" or "abnormal" symptoms, conditions, or diseases in a state where they do not develop (also referred to as manifestation) can be considered to include the concept of "prevention."
[0031] Here, the symptoms, conditions, or diseases are compared before and after administration of the pharmaceutical composition provided by the present invention, or the administration of the pharmaceutical composition provided by the present invention is compared with the administration of a control or placebo. Thus, for example, "treatment of chemotherapeutic drug-induced peripheral neuropathic pain" refers to a concept that includes eliminating, curing, curing, or ameliorating chemotherapeutic drug-induced peripheral neuropathic pain, and actions or means therefor; suppressing chemotherapeutic drug-induced peripheral neuropathic pain, and actions or means therefor; and ameliorating chemotherapeutic drug-induced peripheral neuropathic pain. In another aspect, the concept includes the suppression of chemotherapeutic drug-induced peripheral neuropathic pain symptoms or conditions after administration of a pharmaceutical composition provided by the present invention, which contains an alkalizing agent as an active ingredient, compared to the symptoms or conditions before administration, or the suppression of chemotherapeutic drug-induced peripheral neuropathic pain symptoms or conditions by administration of a pharmaceutical composition provided by the present invention, which contains an alkalizing agent as an active ingredient, compared to placebo administration or a control. For example, "prevention of chemotherapy-induced peripheral neuropathic pain" refers to a concept that includes preventing the onset of chemotherapy-induced peripheral neuropathic pain and actions or means therefor, as well as suppressing the onset of pain before the onset of the pain and actions or means therefor. In another aspect, even if pain occurs when a pharmaceutical composition containing an alkalizing agent as an active ingredient provided by the present invention is administered before the onset of chemotherapy-induced peripheral neuropathic pain, if the pain symptoms or condition are suppressed compared to placebo administration or a control, such a phenomenon can be included in the scope of prevention. The effect of "suppression" above can be evaluated based on the "pain score" described below, in the case of "pain," compared to placebo administration or a control. The concepts of treatment and prevention can be understood by replacing the above "pain" with the symptoms or condition of chemotherapy-induced peripheral neuropathic pain, as already explained. For efficacy evaluation, an appropriate index can be used instead of the "pain score."
[0032] In this specification, the expression [A, B and / or C] means "at least one selected from the group consisting of A, B and C."
[0033] The pharmaceutical compositions provided by the present invention, which contain an alkalinizing agent as an active ingredient, can be administered to humans or other mammals orally or parenterally. Examples of parenteral administration include intravenous administration, subcutaneous administration, intramuscular administration, intraarticular administration, transmucosal administration, transdermal administration, nasal administration, rectal administration, intrathecal administration, intraperitoneal administration, and topical administration.
[0034] The pharmaceutical composition of the present invention, which comprises an alkalinizing agent as an active ingredient, may be prepared by mixing citric acid, a pharmaceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof; or sodium bicarbonate, either as is or with a pharmaceutically acceptable carrier, for example, an excipient (e.g., lactose, D-mannitol, crystalline cellulose, glucose), a binder (e.g., hydroxypropyl cellulose (HPC), gelatin, polyvinylpyrrolidone (PVP)), a lubricant (e.g., magnesium stearate, talc), a disintegrant (e.g., starch, carboxymethylcellulose calcium (CMC-Ca)), a diluent (e.g., water for injection, physiological saline), and, if necessary, other additives (e.g., pH adjuster, surfactant, solubilizer, preservative, emulsifier, isotonicity agent, stabilizer), and may be in the form of a tablet, capsule, suspension, injection, suppository, or other formulation. For example, to prepare a tablet, citric acid, a pharmaceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof; or sodium bicarbonate may be mixed with an excipient (e.g., lactose, D-mannitol, crystalline cellulose, glucose), a disintegrant (e.g., starch, carboxymethylcellulose calcium (CMC-Ca)), a binder (e.g., hydroxypropyl cellulose (HPC), gelatin, polyvinylpyrrolidone (PVP)), a lubricant (e.g., magnesium stearate, talc), etc. The tablet according to the present invention will be described in more detail below.
[0035] In one embodiment, the pharmaceutical composition of the present invention, which comprises an alkalinizing agent as an active ingredient, is a tablet. The tablet of the present invention may contain, in addition to the active ingredient (e.g., potassium citrate or a hydrate thereof; sodium citrate or a hydrate thereof; or a mixture of potassium citrate monohydrate and sodium citrate dihydrate; or sodium bicarbonate), pharmaceutically acceptable additives conventionally used in the pharmaceutical field. Examples of such additives include excipients, binders, disintegrants, flow agents, flavoring agents, lubricants, pH adjusters, surfactants, stabilizers, and flavoring agents. The content of the active ingredient in the tablet of the present invention may be 10 to 95% by weight, preferably 30 to 90% by weight, and more preferably 60 to 85% by weight, of the tablet.
[0036] Examples of excipients that can be used in the tablets provided by the present invention include sugars such as lactose (e.g., lactose hydrate, anhydrous lactose), glucose, sucrose, fructose, maltose, etc., sugar alcohols such as erythritol, sorbitol, maltitol, xylitol, D-mannitol, etc., starch (e.g., corn starch, potato starch, rice starch, wheat starch), crystalline cellulose, magnesium aluminometasilicate, anhydrous calcium phosphate, precipitated calcium carbonate, calcium silicate, calcium lactate, and ethyl cellulose, with crystalline cellulose being particularly preferred. The content of the excipient in the tablets provided by the present invention may be 1 to 95% by weight, preferably 1 to 80% by weight, more preferably 3 to 80% by weight, and even more preferably 3 to 20% by weight, of the tablet.
[0037] Examples of binders that can be used in the tablets provided by the present invention include hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, dextrin, methyl cellulose, polyvinyl alcohol, sodium alginate, aminoalkyl methacrylate copolymer, polyethylene glycol, pregelatinized starch (e.g., partially pregelatinized starch), agar, and gelatin, with hydroxypropyl cellulose being particularly preferred. The content of the binder in the tablets provided by the present invention may be 0.1 to 30% by weight, preferably 0.1 to 10% by weight, and more preferably 0.3 to 3% by weight, based on the weight of the tablet.
[0038] Examples of disintegrants that can be used in the tablets provided by the present invention include croscarmellose sodium, carmellose calcium, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospovidone, starch (e.g., wheat starch, corn starch, partially pregelatinized starch), and carmellose, with partially pregelatinized starch being particularly preferred. The content of the disintegrant in the tablets provided by the present invention may be 0.3 to 20% by weight, preferably 1 to 10% by weight, and more preferably 3 to 10% by weight, based on the weight of the tablet.
[0039] Examples of glidants that can be used in the tablets provided by the present invention include light anhydrous silicic acid, talc, and magnesium aluminometasilicate. The content of the glidant in the tablets provided by the present invention may be 0.03 to 3 wt %, preferably 0.1 to 3 wt %, and more preferably 0.3 to 3 wt %, based on the weight of the tablet.
[0040] Examples of flavoring agents that can be used in the tablets provided by the present invention include acidulants such as citric acid (e.g., anhydrous citric acid), malic acid, acetic acid, tartaric acid, fumaric acid, and ascorbic acid (however, these flavoring agents are not included in the active ingredients of the present invention), and sweeteners such as saccharin sodium, dipotassium glycyrrhizinate, aspartame (registered trademark), stevia, thaumatin, and sucralose. The content of the flavoring agent in the tablets provided by the present invention may be 0.03 to 3% by weight, preferably 0.1 to 3% by weight, and more preferably 0.3 to 3% by weight, of the tablet.
[0041] Examples of lubricants that can be used in the tablets provided by the present invention include magnesium stearate, calcium stearate, talc, light anhydrous silicic acid, sucrose fatty acid esters, carnauba wax, macrogol, and sodium stearyl fumarate, with magnesium stearate being particularly preferred. The content of the lubricant in the tablets provided by the present invention may be 0.1 to 30% by weight, preferably 0.3 to 10% by weight, and more preferably 1 to 3% by weight, based on the weight of the tablet.
[0042] Examples of pH adjusters that can be used in the tablets provided by the present invention include citric acid, phosphates (e.g., sodium dihydrogen phosphate, potassium dihydrogen phosphate), carbonates (e.g., magnesium carbonate, sodium carbonate), tartrates, fumarates, acetates, and amino acid salts (however, the above pH adjusters are not included in the active ingredients of the present invention). The content of the pH adjuster in the tablets provided by the present invention may be 0.1 to 30% by weight, preferably 0.3 to 10% by weight, and more preferably 1 to 5% by weight, of the tablet.
[0043] Examples of surfactants that can be used in the tablets provided by the present invention include sodium lauryl sulfate, polysorbate, sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyl stearate, macrogol, and poloxamer. The content of the surfactant in the tablets provided by the present invention may be 0.01 to 3 wt.%, preferably 0.03 to 1 wt.%, and more preferably 0.03 to 0.5 wt.%, based on the weight of the tablet. Examples of stabilizers that can be used in the tablets provided by the present invention include citric acid (e.g., anhydrous citric acid), malic acid, acetic acid, tartaric acid, maleic acid, ascorbic acid, sodium edetate, and tocopherol (however, these stabilizers are not included in the active ingredients of the present invention), with anhydrous citric acid being particularly preferred. The content of the stabilizer in the tablets provided by the present invention may be 0.01 to 30 wt.%, preferably 0.1 to 30 wt.%, and more preferably 1 to 20 wt.%, based on the weight of the tablet.
[0044] Examples of flavors that can be used in the tablet provided by the present invention include citrus flavors such as lemon, orange, and grapefruit, as well as peppermint, spearmint, and menthol, and can be contained in the tablet in an appropriate amount (for example, 0.01 to 1% by weight, more preferably 0.01 to 0.1% by weight, based on the tablet). The total content of the active ingredient and pharmaceutically acceptable excipients in the tablet provided by the present invention does not exceed 100% by weight of the tablet.
[0045] The tablets provided by the present invention contain the above-mentioned ingredients and can be uncoated tablets without a coating layer, or film-coated tablets with a coating layer. The content of the coating layer can be determined appropriately by those skilled in the art, and may be, for example, 0.1 to 10% by weight of the uncoated tablet. In addition to the coating base, the coating layer can also contain plasticizers, colorants, glossing agents, etc. as appropriate. Examples of coating bases that can be used in the tablets provided by the present invention include hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, cellulose acetate phthalate, methacrylic acid copolymer, and polyvinylpyrrolidone, with hydroxypropyl methylcellulose being particularly preferred. The content of the coating base in the tablets provided by the present invention can be 0.01 to 10% by weight, preferably 0.3 to 3% by weight, of the tablet. Examples of coating plasticizers that can be used in the tablets provided by the present invention include triethyl citrate, medium-chain fatty acid triglycerides, triacetin, glycerin, propylene glycol, and polyethylene glycol (e.g., Macrogol 6000), with Macrogol 6000 being particularly preferred. The content of the coating plasticizer in the tablet provided by the present invention may be 0.01 to 1% by weight, preferably 0.03 to 3% by weight, based on the tablet.
[0046] Examples of coating colorants that can be used in the tablets provided by the present invention include titanium oxide, yellow ferric oxide, ferric oxide, black ferric oxide, Food Blue No. 2, and Food Blue No. 2 aluminum lake. The content of the coating colorant in the tablets provided by the present invention may be 0.01 to 1 wt %, preferably 0.03 to 3 wt %, based on the weight of the tablet. Examples of coating polishing agents that can be used in the tablets provided by the present invention include carnauba wax. The content of the coating polishing agent in the tablets provided by the present invention may be 0.0001 to 0.1 wt %, preferably 0.001 to 0.01 wt %, based on the weight of the tablet.
[0047] The pharmaceutical composition of the present invention containing an alkalizing agent as an active ingredient can be prepared by a method known in the pharmaceutical field. For example, when preparing tablets, the preparation method may include a mixing step of mixing the active ingredient (e.g., potassium citrate or a hydrate thereof; sodium citrate or a hydrate thereof; a mixture of potassium citrate monohydrate and sodium citrate dihydrate; or sodium bicarbonate) with additives, a granulation step, a tableting step, and / or a coating step.
[0048] The mixing step may include a step of mixing the active ingredient with additives such as excipients, stabilizers, disintegrants, and / or binders. Furthermore, the method may further include a step of mixing the mixture containing the active ingredient and additives with a lubricant, flavoring agent, and / or fragrance prior to the tableting step. Mixing can be performed using a V-type mixer, W-type mixer, container mixer, tumbler mixer, stirrer mixer, or the like.
[0049] The granulation step can be carried out by a granulation method known in the pharmaceutical field. Examples of granulation methods include dry granulation, wet granulation, and fluidized bed granulation. In one embodiment, the mixture obtained in the mixing step or the granules obtained in the granulation step can be appropriately pulverized and / or sieved to obtain a mixture or granules having a desired particle size. Pulverization can be carried out using a pulverizer known in the pharmaceutical field, such as a ball mill, jet mill, or hammer mill. Sieving can be carried out using a 16-mesh sieve (opening size: 1000 μm) to 32-mesh sieve (opening size: 500 μm), etc.
[0050] The tableting step can be carried out by a tableting method known in the pharmaceutical field. Examples of tableting methods include direct tableting, dry tableting, wet tableting, and external lubrication tableting. For example, the mixture or granules obtained in the above step can be tableted using a tableting machine known in the pharmaceutical field, such as a single-punch tableting machine or a rotary tableting machine. When a single-punch tableting machine, a rotary tableting machine, or the like is used, a tableting pressure of 1 kN to 30 kN can be used.
[0051] The coating step can be carried out by a method known in the pharmaceutical field, for example, by spray coating the outside of the uncoated tablet with a coating liquid containing a coating base and appropriate additives such as a plasticizer, a colorant, and a glossing agent.
[0052] In one embodiment, the tablet provided by the present invention can be produced by mixing an active ingredient, an excipient (e.g., lactose, D-mannitol, crystalline cellulose, and / or glucose), a binder (e.g., hydroxypropyl cellulose (HPC), gelatin, and / or polyvinylpyrrolidone (PVP)), a stabilizer (e.g., anhydrous citric acid), a disintegrant (e.g., starch (e.g., partially pregelatinized starch) and / or carboxymethylcellulose calcium (CMC-Ca)), and a lubricant (e.g., magnesium stearate), compressing the mixture to obtain a core tablet, and then forming a coating layer on the outer surface of the core tablet, the coating layer including a coating base (e.g., hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and / or PVP), a plasticizer (e.g., triethyl citrate and / or macrogol 6000), a colorant (e.g., red iron oxide and / or titanium oxide), and a glossing agent (e.g., carnauba wax). In one embodiment, the hardness of the resulting tablets may be 10 to 200N, preferably 30 to 150N.
[0053] The amount of alkalizing agent in the pharmaceutical composition of the present invention containing an alkalizing agent as an active ingredient can be appropriately determined. In one embodiment, the amount of alkalizing agent in the pharmaceutical composition of the present invention may be determined so that the dose of the alkalizing agent in a human is an amount that improves acidic urine caused by gout or hyperuricemia when administered to the human, or an amount smaller or larger than that amount, for example, 100 to 800% by mass, 200 to 800% by mass, or 400 to 800% by mass of the daily dose approved in Japan for improving acidic urine caused by gout or hyperuricemia (e.g., when the alkalizing agent is a citric acid preparation: two tablets containing 231.5 mg of potassium citrate (C6H5K3O7.H2O) and 195.0 mg of sodium citrate hydrate (C6H5Na3O7.2H2O) are orally administered three times a day; when the alkalizing agent is sodium bicarbonate: 3 to 5 g are orally administered daily).
[0054] In one embodiment, the pharmaceutical composition of the present invention comprising an alkalinizing agent as an active ingredient is in the form of a tablet, and each tablet may contain 10 mg to 1 g, preferably 100 mg to 500 mg, and more preferably 400 mg to 500 mg, of potassium citrate monohydrate or sodium citrate dihydrate as an active ingredient. In one embodiment, the pharmaceutical composition of the present invention comprising an alkalinizing agent as an active ingredient is in the form of a tablet, and each tablet may contain 10 mg to 300 mg of potassium citrate monohydrate and sodium citrate dihydrate, for a total of 20 mg to 600 mg, preferably 150 to 250 mg of each, for a total of 400 to 500 mg, and more preferably 190 to 240 mg of each, for a total of 400 to 450 mg. In one embodiment, the pharmaceutical composition provided by the present invention comprising an alkalinizing agent as an active ingredient is in the form of a tablet, and one tablet may contain 10 mg to 1 g, preferably 100 mg to 500 mg, of sodium bicarbonate as the alkalinizing agent.
[0055] In one embodiment, the present invention provides a pharmaceutical composition comprising an alkalinizing agent as an active ingredient in the form of a tablet, which contains 231.5 mg of potassium citrate monohydrate and 195.0 mg of sodium citrate dihydrate as active ingredients, and may contain anhydrous citric acid, crystalline cellulose, partially pregelatinized starch, hydroxypropyl cellulose, magnesium stearate, hypromellose, macrogol 6000, titanium oxide, and carnauba wax as excipients.
[0056] In one embodiment, one dosage unit may be a tablet containing 231.5 mg of potassium citrate monohydrate and 195.0 mg of sodium citrate dihydrate. In this specification, "dosage unit" refers to a unit of a formulation, and "one dosage unit" refers to the smallest unit of a formulation. For example, in the case of tablets, a dosage unit is each tablet, and one dosage unit represents one tablet. In the case of an injection, a dosage unit is an injection contained in a sealed container such as an ampoule or vial, and one dosage unit represents an injection contained in a sealed container such as an ampoule or vial. In the case of a powder or jelly formulation, a dosage unit is a powder or jelly formulation sealed in a bag made of a single-layer or multi-layer film sheet such as polyethylene, or a sheet with an aluminum layer on the film sheet, and one dosage unit represents the powder or jelly formulation contained in one sealed bag. In the case of capsules (hard capsules, soft capsules, seamless capsules, etc.), the dosage unit is each capsule, and one dosage unit represents one capsule. When the pharmaceutical composition provided by the present invention is administered to humans or other mammals, one or more of the dosage units may be administered at a time, or one dosage unit may be divided and administered.
[0057] The dosage of the active ingredient is determined appropriately depending on the type of active ingredient, the administration method, the age, weight, sex, symptoms, drug sensitivity of the subject, the administration schedule of the chemotherapy drug, the degree of peripheral neuropathy induced by the chemotherapy drug, etc., but the dosage may be adjusted depending on the administration schedule of the chemotherapy drug, the degree of peripheral neuropathy induced by the chemotherapy drug, and the state of improvement of symptoms.
[0058] In one embodiment, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to a human as an active ingredient, potassium citrate monohydrate and sodium citrate dihydrate may be administered at 1.5 to 6 g / day each for a total of 3 to 12 g / day, 1.5 to 9 g / day each for a total of 3 to 18 g / day, or 1.5 to 12 g / day each for a total of 3 to 24 g / day, preferably 3 to 12 g / day each for a total of 6 to 24 g / day, 3 to 9 g / day each for a total of 6 to 18 g / day, or 6 to 9 g / day each for a total of 12 to 18 g / day, and may be administered in divided doses 1 to 5 times a day, preferably 3 times a day.
[0059] In one embodiment, when potassium citrate monohydrate or sodium citrate dihydrate is orally administered to a human as an active ingredient, it may be administered at a dose of 3 to 24 g / day, 3 to 18 g / day, or 3 to 12 g / day, 1 to 5 times a day, preferably 3 times a day in divided doses. In one embodiment, when sodium bicarbonate is orally administered to a human as an active ingredient, it may be administered at a dose of 2.25 to 9 g / day, 1 to 5 times a day, preferably 3 times a day in divided doses.
[0060] In one embodiment, the pharmaceutical composition of the present invention, which comprises an alkalinizing agent as an active ingredient, may be administered to a subject scheduled for administration of a chemotherapeutic agent and at risk of developing peripheral neuropathy, before the administration of the chemotherapeutic agent, for the purpose of preventing the onset of chemotherapeutic-induced peripheral neuropathy, or may be administered before the administration of the chemotherapeutic agent and continuously after the administration of the chemotherapeutic agent, or may be administered to a subject already experiencing chemotherapeutic-induced peripheral neuropathy, for the purpose of treating the peripheral neuropathy. Such administration may be continued depending on the administration schedule of the chemotherapeutic agent, the degree of chemotherapeutic-induced peripheral neuropathy, and the state of improvement of symptoms. In one embodiment, the pharmaceutical composition provided by the present invention comprising an alkalinizing agent as an active ingredient may be administered chronically, for example, for 1 week, 2 weeks, 3 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 40 weeks, 60 weeks, 80 weeks, 100 weeks, 120 weeks, 1 week or more, 2 weeks or more, 3 weeks or more, 6 weeks or more, 8 weeks or more, 10 weeks or more, 12 weeks or more, 24 weeks or more, 40 weeks or more, 60 weeks or more, 80 weeks or more, 100 weeks or more, 12 weeks or more The treatment is administered for 0 weeks or more, 6 weeks or more and 24 weeks or less, 12 weeks or more and 24 weeks or less, 6 weeks or more and 30 weeks or less, 12 weeks or more and 30 weeks or less, 6 weeks or more and 40 weeks or less, 12 weeks or more and 40 weeks or less, 6 weeks or more and 60 weeks or less, 12 weeks or more and 60 weeks or less, 6 weeks or more and 80 weeks or less, 12 weeks or more and 80 weeks or less, 6 weeks or more and 100 weeks or less, 12 weeks or more and 100 weeks or less, 6 weeks or more and 120 weeks or less, 12 weeks or more and 120 weeks or less, or 24 weeks or more and 120 weeks or less.
[0061] In one embodiment, the pharmaceutical composition provided by the present invention, which comprises an alkalinizing agent as an active ingredient, can be evaluated for its therapeutic or preventive effect on chemotherapy-induced peripheral neuropathy at the time point when the composition is administered continuously every day for two weeks after the administration of the chemotherapy agent.
[0062] <Anti-cancer pharmaceutical composition suppressing the onset of peripheral neuropathy induced by a cancer chemotherapeutic agent> In one embodiment, the present invention provides an anti-cancer pharmaceutical composition suppressing the onset of peripheral neuropathy induced by a cancer chemotherapeutic agent, the anti-cancer pharmaceutical composition comprising an alkalizing agent and a cancer chemotherapeutic agent as active ingredients. As described above, it is known that some cancer chemotherapeutic agents tend to induce peripheral neuropathy. Therefore, by combining an alkalizing agent with an anti-cancer agent that can induce peripheral neuropathy to form a combination drug, it is possible to provide an anti-cancer pharmaceutical composition suppressing the onset of peripheral neuropathy induced by a cancer chemotherapeutic agent.
[0063] In one aspect, the "anticancer pharmaceutical composition in which the onset of peripheral neuropathy induced by a cancer chemotherapy drug is suppressed" refers to an anticancer pharmaceutical composition in which the onset of peripheral neuropathy induced by an anticancer drug is suppressed compared to an "anticancer pharmaceutical composition without an alkalizing agent" containing an anticancer drug in an amount equivalent to the content of the anticancer drug contained in the anticancer pharmaceutical composition provided by the present invention. In another aspect, the "anticancer pharmaceutical composition in which the onset of peripheral neuropathy induced by a cancer chemotherapy drug is suppressed" refers to an anticancer pharmaceutical composition in which the onset of peripheral neuropathy induced by a cancer chemotherapy drug is not suppressed. In yet another aspect, the "anticancer pharmaceutical composition in which the onset of peripheral neuropathy induced by a cancer chemotherapy drug is suppressed" refers to an anticancer pharmaceutical composition in which the onset of peripheral neuropathy induced by an anticancer drug is suppressed by 90% or less compared to an "anticancer pharmaceutical composition without an alkalizing agent" containing an anticancer drug in an amount equivalent to the content of the anticancer drug contained in the anticancer pharmaceutical composition provided by the present invention. The onset of peripheral neuropathy is preferably 85% or less, more preferably 82% or less. In one aspect, the inhibition rate of the onset of peripheral neuropathy is 0 to 90%, in another aspect 0 to 85%, in yet another aspect 0 to 82%, in yet another aspect 20 to 85%, in yet another aspect 20 to 82%, in yet another aspect 30 to 82%, in yet another aspect 40 to 82%, and in yet another aspect 42 to 82%. Here, the inhibition rate of the onset of peripheral neuropathy can be calculated based on an appropriate evaluation index, such as the "pain score" described below, for example, in the case of "pain."
[0064] In one embodiment, examples of the cancer chemotherapeutic drug (also referred to as an anticancer drug) contained as an active ingredient in the anticancer pharmaceutical composition provided by the present invention, which suppresses the onset of peripheral neuropathy induced by a cancer chemotherapeutic drug, include cytotoxic anticancer drugs such as paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine; bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, and brentuximab. Examples of the anticancer drug include at least one anticancer drug selected from the group consisting of molecularly targeted anticancer drugs such as vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib; immunotherapeutic drugs such as nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab; and other anticancer drugs such as cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide, and pomalidomide. At least one anticancer drug selected from the group consisting of paclitaxel, vincristine, oxaliplatin, and bortezomib is preferred, and paclitaxel or oxaliplatin is particularly preferred.
[0065] In one embodiment, the alkalizing agent contained as an active ingredient in the anticancer pharmaceutical composition provided by the present invention, which suppresses the onset of peripheral neuropathy induced by a cancer chemotherapeutic agent, can be the aforementioned pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof, or sodium bicarbonate. In the anticancer pharmaceutical composition provided by the present invention, which suppresses the onset of peripheral neuropathy induced by a cancer chemotherapeutic agent, the blending ratio of the alkalizing agent to the cancer chemotherapeutic agent varies depending on the peripheral neuropathy-inducing ability of the cancer chemotherapeutic agent to be blended, etc., but in one embodiment, when the alkalizing agent is sodium citrate, potassium citrate, a hydrate thereof, or a mixture thereof, the alkalizing agent can be 10 to 10,000 parts by mass, preferably 20 to 6,000 parts by mass, and more preferably 30 to 5,500 parts by mass, per part by mass of the anticancer drug.
[0066] In one embodiment, when the alkalizing agent is sodium citrate, potassium citrate, a hydrate thereof, or a mixture thereof and the anticancer drug is paclitaxel, the amount of the alkalizing agent may be 10 to 150 parts by mass, preferably 20 to 100 parts by mass, and more preferably 30 to 90 parts by mass, per part by mass of the anticancer drug. In one embodiment, when the alkalizing agent is sodium citrate, potassium citrate, a hydrate thereof, or a mixture thereof and the anticancer drug is oxaliplatin, the amount of the alkalizing agent may be 10 to 150 parts by mass, preferably 30 to 120 parts by mass, and more preferably 50 to 85 parts by mass, per part by mass of the anticancer drug. In one embodiment, when the alkalizing agent is sodium citrate, potassium citrate, a hydrate thereof, or a mixture thereof and the anticancer drug is vincristine, the amount of the alkalizing agent may be 1,000 to 10,000 parts by mass, preferably 3,000 to 7,000 parts by mass, and more preferably 4,500 to 5,500 parts by mass per part by mass of the anticancer drug. In one embodiment, when the alkalizing agent is sodium citrate, potassium citrate, a hydrate thereof, or a mixture thereof and the anticancer drug is bortezomib, the amount of the alkalizing agent may be 1,000 to 10,000 parts by mass, preferably 3,000 to 7,000 parts by mass, and more preferably 5,000 to 6,000 parts by mass per part by mass of the anticancer drug.
[0067] In one embodiment, the anticancer pharmaceutical composition provided by the present invention, which suppresses the onset of peripheral neuropathy induced by a cancer chemotherapy drug, can be administered to a subject suffering from cancer, such as a human or other mammal, thereby treating the cancer while suppressing the onset of peripheral neuropathy. The cancer to be treated is determined by the type of anticancer drug contained as an active ingredient in the anticancer pharmaceutical composition provided by the present invention. The anticancer drugs exemplified above are known per se, and therefore the cancers against which each anticancer drug is effective are also known. For example, when the active ingredient is paclitaxel, it is known to be effective against non-small cell lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, angiosarcoma, germ cell tumor, etc. When the active ingredient is oxaliplatin, it is known to be effective against colon cancer, gastric cancer, pancreatic cancer, or small intestine cancer. When the anticancer drug active ingredient is vincristine, it is known to be effective against leukemia, malignant lymphoma, pediatric tumors, multiple myeloma, glioma, or pheochromocytoma. When the anticancer drug active ingredient is bortezomib, it is known to be effective against multiple myeloma, mantle cell lymphoma, primary macroglobulinemia, or lymphoplasmacytic lymphoma. In one embodiment, the anticancer pharmaceutical composition provided by the present invention, which suppresses the development of peripheral neuropathy induced by a cancer chemotherapy drug, may be effective against cancers for which the anticancer drug active ingredient is effective.
[0068] In one embodiment, the anticancer pharmaceutical composition provided by the present invention, which suppresses the onset of peripheral neuropathy induced by a cancer chemotherapeutic drug, is administered orally or parenterally to a subject suffering from cancer, such as a human or other mammal. Examples of parenteral administration include intravenous administration, subcutaneous administration, intramuscular administration, intra-articular administration, transmucosal administration, transdermal administration, nasal administration, rectal administration, intrathecal administration, intraperitoneal administration, and topical administration. In one embodiment, when the anticancer drug as the active ingredient of the anticancer pharmaceutical composition provided by the present invention is a known anticancer drug, the anticancer pharmaceutical composition provided by the present invention can be administered to a subject in need of cancer treatment according to an established administration method and administration regimen for the anticancer drug. By applying the anticancer pharmaceutical composition provided by the present invention, which suppresses the onset of peripheral neuropathy induced by cancer chemotherapy drugs, the onset of peripheral neuropathy can be suppressed, making it possible to continue cancer treatment using the anticancer drug even in subjects who have been unable to continue treatment with conventional anticancer drugs due to the onset of peripheral neuropathy, and this can also improve the subject's quality of life, thereby enabling more effective cancer treatment than conventional cancer treatments. In one embodiment, when the anticancer drug serving as the active ingredient of the anticancer pharmaceutical composition provided by the present invention is a known anticancer drug, the anticancer pharmaceutical composition provided by the present invention can be formulated in accordance with known formulations containing the anticancer drug. In one embodiment, the formulation technology described above for pharmaceutical compositions containing an alkalizing agent as an active ingredient can be applied to the anticancer pharmaceutical composition provided by the present invention.
[0069] 2. Combination Preparations In one embodiment, the present invention provides a combination preparation for simultaneous, separate, or sequential administration in the treatment of cancer, which includes at least two separate formulations of an alkalizing agent and a cancer chemotherapeutic agent, and which suppresses the onset of peripheral neuropathy. The alkalizing agent and cancer chemotherapeutic agent in the combination preparation may be the alkalizing agent and cancer chemotherapeutic agent, respectively, previously disclosed formulations, and the alkalizing agent formulation and cancer chemotherapeutic agent formulation may also be the formulations previously disclosed. The cancer to be treated with the combination preparation is determined by the type of cancer chemotherapeutic agent (also referred to as an anticancer drug) included in the combination preparation provided by the present invention. The anticancer drugs exemplified above are known anticancer drugs, and the cancers for which each anticancer drug is effective are also known.
[0070] The term "simultaneous administration" as used herein in connection with the combination preparation means that the alkalinizing agent formulation and the cancer chemotherapy drug formulation contained in the combination preparation are administered simultaneously at the appropriate time. The term "separately administration" as used herein in connection with the combination preparation means that the alkalinizing agent formulation and the cancer chemotherapy drug formulation contained in the combination preparation are administered at different times during the course of a common treatment schedule. The term "sequential administration" as used herein in connection with the combination preparation means that the administration of one alkalinizing agent formulation and the cancer chemotherapy drug formulation contained in the combination preparation is followed by the administration of the other formulation. This means that the other formulation can be administered immediately after the administration of one formulation, or within the time period during which the effectiveness of the other formulation is maintained after the administration of one formulation, or within the time period during which the effectiveness of the other formulation is maintained after the administration of one formulation repeatedly for a certain period of time.
[0071] By applying the combination preparation, it is possible to provide a cancer treatment in which the onset of peripheral neuropathy induced by cancer chemotherapeutic agents is suppressed. By applying the combination preparation provided by the present invention, the onset of peripheral neuropathy induced by cancer chemotherapeutic agents can be suppressed. Therefore, even in subjects who have been unable to continue cancer treatment with conventional anticancer drugs due to the onset of peripheral neuropathy, it becomes possible to continue cancer treatment using the anticancer drug, and the subject's quality of life can also be improved, thereby enabling more effective cancer treatment than conventional cancer treatments. The content ratio of the alkalinizing agent to the cancer chemotherapeutic agent in the combination preparation provided by the present invention can be determined in accordance with the content ratio of the alkalinizing agent to the cancer chemotherapeutic agent in the above-mentioned anticancer pharmaceutical composition in which the onset of peripheral neuropathy induced by cancer chemotherapeutic agents is suppressed.
[0072] 3. Pharmaceutical Kit In one embodiment, the present invention provides an anti-cancer pharmaceutical kit for suppressing the onset of peripheral neuropathy, comprising an alkalizing agent in a first compartment and a cancer chemotherapeutic agent in a second compartment. The alkalizing agent and cancer chemotherapeutic agent in the pharmaceutical kit may be previously disclosed alkalizing agents and cancer chemotherapeutic agents, respectively. Preferably, the alkalizing agent contained in the first compartment and the cancer chemotherapeutic agent contained in the second compartment are each formulated, and previously disclosed formulations may also be used for the alkalizing agent formulation and the cancer chemotherapeutic agent formulation. The cancer to be treated in the pharmaceutical kit is determined by the type of cancer chemotherapeutic agent (also referred to as anticancer drug) contained in the pharmaceutical kit provided by the present invention. The anticancer drugs exemplified above are known anticancer drugs, and the cancers against which each anticancer drug is effective are also known. In one embodiment, the first compartment is further divided into two or more compartments depending on the number of administrations and dosage of the alkalinizing agent contained therein, and each compartment can contain an alkalinizing agent suitable for a single administration. In one embodiment, the second compartment is further divided into two or more compartments depending on the number of administrations and dosage of the cancer chemotherapy drug contained therein, and each compartment can contain a cancer chemotherapy drug suitable for a single administration.
[0073] By applying the pharmaceutical kit, it is possible to provide a cancer treatment in which the onset of peripheral neuropathy induced by a cancer chemotherapeutic agent is suppressed. By applying the pharmaceutical kit provided by the present invention, the onset of peripheral neuropathy induced by a cancer chemotherapeutic agent can be suppressed. Therefore, even in subjects who have been unable to continue cancer treatment with conventional anticancer drugs due to the onset of peripheral neuropathy, it becomes possible to continue cancer treatment using the anticancer drug, and the subject's quality of life can also be improved, thereby enabling more effective cancer treatment than conventional cancer treatments. The content ratio of the alkalinizing agent to the cancer chemotherapeutic agent in the pharmaceutical kit provided by the present invention can be determined in accordance with the content ratio of the alkalinizing agent to the cancer chemotherapeutic agent in the anticancer pharmaceutical composition for suppressing the onset of peripheral neuropathy induced by a cancer chemotherapeutic agent.
[0074] Examples of other embodiments of the present invention include the following. <1-1> An alkalinizing agent or a pharmaceutical composition containing an alkalinizing agent for use in the treatment or prevention of peripheral neuropathy induced by a chemotherapeutic agent. <1-2> An alkalinizing agent or a pharmaceutical composition containing an alkalinizing agent for the use according to <1-1>, wherein the peripheral neuropathy induced by a chemotherapeutic agent is pain, sensory disorder, motor disorder, autonomic neuropathy, or a complication thereof caused by peripheral neuropathy. <1-3> An alkalinizing agent or a pharmaceutical composition containing an alkalinizing agent for the use according to <1-1> or <1-2>, wherein the peripheral neuropathy induced by a chemotherapeutic agent is peripheral neuropathic pain. <1-4> An alkalinizing agent or a pharmaceutical composition containing an alkalinizing agent for the use according to <1-3>, wherein the peripheral neuropathic pain is shooting pain, burning pain, pain (excluding shooting pain and burning pain), or tingling. <1-5> An alkalinizing agent or a pharmaceutical composition comprising an alkalinizing agent for the use according to <1-1> or <1-2>, wherein the peripheral neuropathy induced by a chemotherapy drug is a sensory disorder caused by peripheral neuropathy. <1-6> An alkalinizing agent or a pharmaceutical composition comprising an alkalinizing agent for the use according to <1-5>, wherein the sensory disorder caused by peripheral neuropathy is hypoesthesia, hyperesthesia, or dysesthesia. <1-7> An alkalinizing agent or a pharmaceutical composition comprising an alkalinizing agent for the use according to <1-6>, wherein the hyperesthesia is allodynia and the dysesthesia is dysesthesia or paresthesia. <1-8> An alkalinizing agent or a pharmaceutical composition comprising an alkalinizing agent for the use according to <1-1> or <1-2>, wherein the peripheral neuropathy induced by a chemotherapy drug is an autonomic neuropathy caused by peripheral neuropathy. <1-9> An alkalinizing agent or a pharmaceutical composition comprising an alkalinizing agent for use according to <1-8>, wherein the symptom caused by autonomic nervous system disorder is dysuria, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus.<1-10> The alkalinizing agent or the pharmaceutical composition comprising the alkalinizing agent for use according to any one of <1-1> to <1-9>, wherein the peripheral neuropathy induced by a chemotherapy drug is peripheral neuropathy in which symptoms appear in the limbs.
[0075] <1-11> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent for the use according to any one of <1-1> to <1-10>, wherein the alkalizing agent is a pharmaceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof. <1-12> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent for the use according to any one of <1-1> to <1-11>, wherein the alkalizing agent is sodium citrate, potassium citrate, or a hydrate thereof, or a mixture thereof. <1-13> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent for the use according to any one of <1-1> to <1-12>, wherein the alkalizing agent comprises a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof. <1-14> An alkalizing agent or a pharmaceutical composition containing an alkalizing agent, for use according to any one of <1-1> to <1-13>, wherein the alkalizing agent is sodium citrate or a hydrate thereof.
[0076] <1-15> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent, for the use according to any one of <1-1> to <1-14>, wherein the pharmaceutical composition is a tablet. <1-16> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent, for the use according to any one of <1-1> to <1-10>, wherein the alkalizing agent is sodium bicarbonate. <1-17> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent, for the use according to any one of <1-1> to <1-16>, wherein the chemotherapeutic drug is a cancer chemotherapeutic drug. <1-18> A pharmaceutical composition comprising an alkalizing agent or an alkalizing agent, for the use according to <1-17>, wherein the cancer chemotherapeutic drug is a cytotoxic anticancer drug, a molecularly targeted anticancer drug, an immunotherapeutic drug, or another anticancer drug. <1-19> An alkalinizing agent or a pharmaceutical composition comprising an alkalinizing agent for use according to <1-18>, wherein the cytotoxic anticancer drug is at least one anticancer drug selected from the group consisting of paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine. <1-20> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent for the use according to <1-18>, wherein the molecularly targeted anticancer drug is at least one anticancer drug selected from the group consisting of bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, brentuximab vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib. <1-21> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent for the use according to <1-18>, wherein the immunotherapeutic drug is at least one anticancer drug selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab. <1-22> An alkalinizing agent or a pharmaceutical composition comprising an alkalinizing agent for use according to <1-18>, wherein the other anticancer drug is at least one anticancer drug selected from the group consisting of cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide, and pomalidomide.<1-23> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent for the use according to <1-17>, wherein the cancer chemotherapy drug is at least one anticancer drug selected from the group consisting of paclitaxel, vincristine, oxaliplatin, and bortezomib. <1-24> An alkalizing agent or a pharmaceutical composition comprising an alkalizing agent for the use according to <1-23>, wherein the cancer chemotherapy drug is paclitaxel or oxaliplatin.
[0077] <1-25> A combined preparation for use in the treatment of cancer in which the onset of peripheral neuropathy is suppressed, the combined preparation comprising at least two separate preparations of an alkalizing agent and a cancer chemotherapeutic agent, for simultaneous, separate, or sequential administration. <1-26> A combined preparation for use according to <1-25>, wherein the peripheral neuropathy is pain, sensory disorder, motor disorder, autonomic neuropathy, or a complication thereof, caused by peripheral neuropathy. <1-27> A combined preparation for use according to <1-25> or <1-26>, wherein the peripheral neuropathy is peripheral neuropathic pain. <1-28> A combined preparation for use according to <1-27>, wherein the peripheral neuropathic pain is shooting pain, burning pain, pain (excluding shooting pain and burning pain), or tingling. <1-29> A combination preparation for the use according to <1-25> or <1-26>, wherein the peripheral neuropathy is a sensory disorder caused by peripheral neuropathy. <1-30> A combination preparation for the use according to <1-29>, wherein the sensory disorder caused by peripheral neuropathy is hypoesthesia, hyperesthesia, or dysesthesia. <1-31> A combination preparation for the use according to <1-30>, wherein the hyperesthesia is allodynia and the dysesthesia is dysesthesia or paresthesia. <1-32> A combination preparation for the use according to <1-25> or <1-26>, wherein the peripheral neuropathy is an autonomic neuropathy caused by peripheral neuropathy. <1-33> A combination preparation for the use according to <1-32>, wherein the symptom caused by autonomic neuropathy is dysuria, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus. <1-34> The combined preparation for use according to any one of <1-25> to <1-33>, wherein the peripheral neuropathy is a peripheral neuropathy in which symptoms appear in the limbs.
[0078] <1-35> A combination preparation for use according to any one of <1-25> to <1-34>, wherein the alkalizing agent is a pharmaceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof. <1-36> A combination preparation for use according to any one of <1-25> to <1-35>, wherein the alkalizing agent is sodium citrate, potassium citrate, or a hydrate thereof, or a mixture thereof. <1-37> A combination preparation for use according to any one of <1-25> to <1-36>, wherein the alkalizing agent comprises a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof. <1-38> A combination preparation for use according to any one of <1-25> to <1-37>, wherein the alkalizing agent is sodium citrate or a hydrate thereof.
[0079] <1-39> A combination preparation for use according to any one of <1-25> to <1-34>, wherein the alkalinizing agent is sodium bicarbonate. <1-40> A combination preparation for use according to any one of <1-25> to <1-39>, wherein the cancer chemotherapeutic drug is a cytotoxic anticancer drug, a molecularly targeted anticancer drug, an immunotherapeutic drug, or another anticancer drug. <1-41> A combination preparation for use according to <1-40>, wherein the cytotoxic anticancer drug is at least one anticancer drug selected from the group consisting of paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine. <1-42> The combination preparation for use according to <1-40>, wherein the molecularly targeted anticancer drug is at least one anticancer drug selected from the group consisting of bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, brentuximab vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib. <1-43> The combination preparation for use according to <1-40>, wherein the immunotherapeutic drug is at least one anticancer drug selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab. <1-44> A combination preparation for use according to <1-40>, wherein the other anticancer drug is at least one anticancer drug selected from the group consisting of cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide, and pomalidomide. <1-45> A combination preparation for use according to any one of <1-25> to <1-39>, wherein the cancer chemotherapeutic drug is at least one anticancer drug selected from the group consisting of paclitaxel, vincristine, oxaliplatin, and bortezomib. <1-46> A combination preparation for use according to <1-45>, wherein the cancer chemotherapeutic drug is paclitaxel or oxaliplatin.
[0080] <1-47> An anti-cancer pharmaceutical composition for use in treating cancer in which the onset of peripheral neuropathy is suppressed, comprising an alkalinizing agent and a cancer chemotherapeutic drug. <1-48> The anti-cancer pharmaceutical composition for use according to <1-47>, wherein the peripheral neuropathy is pain, sensory disorder, motor disorder, autonomic neuropathy, or a complication thereof caused by peripheral neuropathy. <1-49> The anti-cancer pharmaceutical composition for use according to <1-47> or <1-48>, wherein the peripheral neuropathy is peripheral neuropathic pain. <1-50> The anti-cancer pharmaceutical composition for use according to <1-49>, wherein the peripheral neuropathic pain is shooting pain, burning pain, pain (excluding shooting pain and burning pain), or tingling. <1-51> The anti-cancer pharmaceutical composition for use according to <1-47> or <1-48>, wherein the peripheral neuropathy is sensory disorder caused by peripheral neuropathy. <1-52> The anticancer pharmaceutical composition for use according to <1-51>, wherein the sensory disorder caused by peripheral neuropathy is hypoesthesia, hyperesthesia, or dysesthesia. <1-53> The anticancer pharmaceutical composition for use according to <1-52>, wherein the hyperesthesia is allodynia and the dysesthesia is dysesthesia or paresthesia. <1-54> The anticancer pharmaceutical composition for use according to <1-47> or <1-48>, wherein the peripheral neuropathy is autonomic neuropathy caused by peripheral neuropathy. <1-55> The anticancer pharmaceutical composition for use according to <1-54>, wherein the symptom caused by autonomic neuropathy is dysuria, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus. <1-56> The anticancer pharmaceutical composition for use according to any one of <1-47> to <1-55>, wherein the peripheral neuropathy is peripheral neuropathy whose symptoms appear in the limbs.
[0081] <1-57> The anti-cancer pharmaceutical composition for use according to any one of <1-47> to <1-56>, wherein the alkalizing agent is a pharmaceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof. <1-58> The anti-cancer pharmaceutical composition for use according to any one of <1-47> to <1-57>, wherein the alkalizing agent is sodium citrate, potassium citrate, or a hydrate thereof, or a mixture thereof. <1-59> The anti-cancer pharmaceutical composition for use according to any one of <1-47> to <1-58>, wherein the alkalizing agent comprises a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof. <1-60> The anti-cancer pharmaceutical composition for use according to any one of <1-47> to <1-59>, wherein the alkalizing agent is sodium citrate or a hydrate thereof.
[0082] <1-61> The anticancer pharmaceutical composition for use according to any one of <1-47> to <1-56>, wherein the alkalinizing agent is sodium bicarbonate. <1-62> The anticancer pharmaceutical composition for use according to any one of <1-47> to <1-61>, wherein the cancer chemotherapeutic drug is a cytotoxic anticancer drug, a molecularly targeted anticancer drug, an immunotherapeutic drug, or another anticancer drug. <1-63> The anticancer pharmaceutical composition for use according to <1-62>, wherein the cytotoxic anticancer drug is at least one anticancer drug selected from the group consisting of paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine. <1-64> The anticancer pharmaceutical composition for use according to <1-62>, wherein the molecularly targeted anticancer drug is at least one anticancer drug selected from the group consisting of bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, brentuximab vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib. <1-65> The anticancer pharmaceutical composition for use according to <1-62>, wherein the immunotherapeutic drug is at least one anticancer drug selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab. <1-66> The anticancer pharmaceutical composition for use according to <1-62>, wherein the other anticancer drug is at least one anticancer drug selected from the group consisting of cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide, and pomalidomide. <1-67> The anticancer pharmaceutical composition for use according to any one of <1-47> to <1-61>, wherein the cancer chemotherapeutic drug is at least one anticancer drug selected from the group consisting of paclitaxel, vincristine, oxaliplatin, and bortezomib. <1-68> The anticancer pharmaceutical composition for use according to <1-67>, wherein the cancer chemotherapeutic drug is paclitaxel or oxaliplatin.
[0083] <1-69> A pharmaceutical kit for use in treating cancer in which the onset of peripheral neuropathy is suppressed, the pharmaceutical kit comprising an alkalinizing agent in a first compartment and a cancer chemotherapeutic drug in a second compartment. <1-70> The pharmaceutical kit for use according to <1-69>, wherein the peripheral neuropathy is pain, sensory disorder, motor disorder, autonomic neuropathy, or a complication thereof caused by peripheral neuropathy. <1-71> The pharmaceutical kit for use according to <1-69> or <1-70>, wherein the peripheral neuropathy is peripheral neuropathic pain. <1-72> The pharmaceutical kit for use according to <1-71>, wherein the peripheral neuropathic pain is shooting pain, burning pain, pain (excluding shooting pain and burning pain), or tingling. <1-73> A pharmaceutical kit for the use according to <1-69> or <1-70>, wherein the peripheral neuropathy is a sensory disorder caused by peripheral neuropathy. <1-74> A pharmaceutical kit for the use according to <1-73>, wherein the sensory disorder caused by peripheral neuropathy is hypoesthesia, hyperesthesia, or dysesthesia. <1-75> A pharmaceutical kit for the use according to <1-74>, wherein the hyperesthesia is allodynia and the dysesthesia is dysesthesia or paresthesia. <1-76> A pharmaceutical kit for the use according to <1-69> or <1-70>, wherein the peripheral neuropathy is an autonomic neuropathy caused by peripheral neuropathy. <1-77> A pharmaceutical kit for the use according to <1-76>, wherein the symptom caused by autonomic neuropathy is dysuria, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus. <1-78> A pharmaceutical kit for use according to any one of <1-69> to <1-77>, wherein the peripheral neuropathy is a peripheral neuropathy in which symptoms appear in the limbs.
[0084] <1-79> A pharmaceutical kit for use according to any one of <1-69> to <1-78>, wherein the alkalizing agent is a pharmaceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof. <1-80> A pharmaceutical kit for use according to any one of <1-69> to <1-79>, wherein the alkalizing agent is sodium citrate, potassium citrate, or a hydrate thereof, or a mixture thereof. <1-81> A pharmaceutical kit for use according to any one of <1-69> to <1-80>, wherein the alkalizing agent comprises a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof. <1-82> A pharmaceutical kit for use according to any one of <1-69> to <1-81>, wherein the alkalizing agent is sodium citrate or a hydrate thereof.
[0085] <1-83> A pharmaceutical kit for use according to any one of <1-69> to <1-78>, wherein the alkalinizing agent is sodium bicarbonate. <1-84> A pharmaceutical kit for use according to any one of <1-69> to <1-83>, wherein the cancer chemotherapeutic drug is a cytotoxic anticancer drug, a molecularly targeted anticancer drug, an immunotherapeutic drug, or another anticancer drug. <1-85> A pharmaceutical kit for use according to <1-84>, wherein the cytotoxic anticancer drug is at least one anticancer drug selected from the group consisting of paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine. <1-86> The pharmaceutical kit for use according to <1-84>, wherein the molecularly targeted anticancer drug is at least one anticancer drug selected from the group consisting of bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, brentuximab vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib. <1-87> The pharmaceutical kit for use according to <1-84>, wherein the immunotherapeutic drug is at least one anticancer drug selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab. <1-88> A pharmaceutical kit for use according to <1-84>, wherein the other anticancer drug is at least one anticancer drug selected from the group consisting of cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide, and pomalidomide. <1-89> A pharmaceutical kit for use according to any one of <1-69> to <1-83>, wherein the cancer chemotherapeutic drug is at least one anticancer drug selected from the group consisting of paclitaxel, vincristine, oxaliplatin, and bortezomib. <1-90> A pharmaceutical kit for use according to <1-89>, wherein the cancer chemotherapeutic drug is paclitaxel or oxaliplatin.
[0086] <2-1> A method for treating or preventing chemotherapy-induced peripheral neuropathy, which comprises administering an effective amount of an alkalizing agent to a subject in need of such treatment or prevention. <2-2> A method for treating cancer, in which the onset of peripheral neuropathy is suppressed, which comprises administering effective amounts of an alkalizing agent and a cancer chemotherapy drug simultaneously, separately, or sequentially to a subject in need of cancer treatment.
[0087] <3-1> Use of an alkalizing agent for producing a pharmaceutical composition for treating or preventing peripheral neuropathy induced by a chemotherapy drug. <3-2> Use of an alkalizing agent and a cancer chemotherapy drug for producing a combined preparation to be administered simultaneously, separately, or sequentially in the treatment of cancer, wherein the combined preparation suppresses the onset of peripheral neuropathy. <3-3> Use of an alkalizing agent and a cancer chemotherapy drug for producing an anti-cancer pharmaceutical composition in which the onset of peripheral neuropathy is suppressed. <3-4> Use of an alkalizing agent and a cancer chemotherapy drug for producing an anti-cancer pharmaceutical kit in which the onset of peripheral neuropathy is suppressed, comprising an alkalizing agent in a first compartment and a cancer chemotherapy drug in a second compartment.
[0088] 4. Food Composition In one embodiment, the present invention may provide an alkalizing agent or a food composition comprising an alkalizing agent for non-therapeutic use in suppressing peripheral neuropathy induced by a chemotherapy drug.
[0089] The alkalinizing agent may be any of those described in "1. Pharmaceutical Compositions" above. Examples of the alkalinizing agent include pharmaceutically acceptable salts of citric acid (e.g., alkali metal citrates, their hydrates, or mixtures thereof) or sodium bicarbonate, which are acceptable as foodstuffs. Preferably, the alkalinizing agent is a mixture of potassium citrate monohydrate (C6H5K3O7.H2O) and sodium citrate dihydrate (C6H5Na3O7.2H2O), or sodium citrate dihydrate.
[0090] The content of citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof; or sodium bicarbonate in the food composition provided by the present invention can be appropriately determined depending on the type of food. Examples of food compositions include foods for specified health uses, foods with functional claims, foods for hospital patients, and supplements. The form of these food compositions is not particularly limited as long as they contain an effective amount of an alkalizing agent to achieve the above-mentioned effect and are orally ingestible. They may be in the form of ordinary food or beverages, or may be provided as a formulation suitable for oral administration, such as tablets, capsules, or suspensions, which can be used in the pharmaceutical compositions. The composition and production method of these formulations can be directly applied to the composition and production method of the pharmaceutical formulation described in "1. Pharmaceutical Compositions" above, or any formulation technology known per se in the field of pharmaceutical formulation technology can be applied.
[0091] For example, in the case of a food for specified health uses, a food with functional claims, a food for hospital patients, or a supplement, a single serving of food may contain a total of 1 to 3 g (one-third of a serving) of potassium citrate monohydrate and sodium citrate dihydrate as active ingredients. When a food for specified health uses, a food with functional claims, a food for hospital patients, or a supplement is provided as a tablet, for example, a 300 mg to 600 mg tablet may contain 70 to 80 wt% of citric acid, a pharmaceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof.
[0092] When the food composition of the present invention is not formulated but is provided in the form of a conventional food or beverage, it can be prepared appropriately by those skilled in the art depending on the type of food. For example, it can be prepared by blending citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof (e.g., potassium citrate and / or sodium citrate), or sodium bicarbonate with a food ingredient. Examples of the food or beverage form include liquid, milky, or paste-like foods such as beverages, soy sauce, milk, yogurt, and miso; semi-solid foods such as jellies and gummies; solid foods such as candy, gum, tofu, and supplements; and powdered foods. Examples of beverages include fruit juice drinks, coffee drinks, oolong tea drinks, green tea drinks, black tea drinks, barley tea drinks, vegetable drinks, carbonated soft drinks, fruit extract drinks, vegetable extract juices, near-water, sports drinks, and diet drinks.
[0093] The beverage may contain additives, such as antioxidants, flavorings, various esters, organic acids, organic acid salts, inorganic acids, inorganic acid salts, inorganic salts, colorants, emulsifiers, preservatives, seasonings, sweeteners, acidulants, fruit juice extracts, vegetable extracts, nectar extracts, pH adjusters, and quality stabilizers, either alone or in combination. The food composition provided by the present invention can be used in the same manner as the pharmaceutical composition described above in "1. Pharmaceutical Composition," and can also be used for purposes other than the treatment or prevention of disease (also referred to as non-therapeutic uses). That is, the food composition can be applied to a subject to which the pharmaceutical composition is to be applied such that the amount of alkalinizing agent used in the food composition is the same as the amount of alkalinizing agent contained in the pharmaceutical composition. In one embodiment, the "food composition" of the present invention can be ingested within the non-therapeutic range by a subject (e.g., a human or other mammal) currently receiving or about to receive a chemotherapy drug to suppress the onset of peripheral neuropathy or to suppress previously occurring peripheral neuropathy. In this case, whether the alkalinizing agent is a component of a pharmaceutical composition or a food composition, the pharmacological effect of the alkalinizing agent itself is basically the same, so the amount and method of application of the food composition can be adjusted appropriately based on the alkalinizing agent depending on the expected effect.
[0094] Food compositions that are applied to subjects (e.g., humans or other mammals) who do not have any "pathological" or "abnormal" symptoms, conditions, or diseases, i.e., subjects (e.g., humans or other mammals) who are in a "healthy" or "normal" state, in order to maintain or promote the "healthy" or "normal" state, are sometimes specifically referred to as "foods with functional claims."
[0095] The term "administration" described in "1. Pharmaceutical Composition" above can also be applied to the "food composition" of the present invention, and furthermore, with regard to the "food composition" of the present invention, the term "administration" can be read as "ingestion." Therefore, for example, the terms "administer," "administered," etc. can be read as "ingested," "taken," "ingested," etc., depending on the context.
[0096] The present invention will be further explained below with reference to examples, but the present invention is not limited to these examples.
[0097] Example 1: Evaluation of an Alkalizing Agent in an Oxaliplatin-Induced Mouse Neuropathic Pain Model (Test Substance) The alkalinizing agent used was a mixture of 463 mg of potassium citrate monohydrate (C6H5K3O7·H2O), 390 mg of sodium citrate dihydrate (C6H5Na3O7·2H2O), and 147 mg of pharmaceutically acceptable additives (Uralyt U Powder, manufactured by Nippon Chemiphar Co., Ltd.) per gram of dry weight. The required amount of Uralyt U Powder (hereinafter simply referred to as "Uralyt") was weighed and dissolved in water for injection to achieve the desired concentration before use. Injectable water, the solvent for the alkalinizing agent, was used in the sham and control groups. (Animals) Six-week-old male C57BL / 6J mice (Japan SLC Co., Ltd.) were used. After allowing the animals to adapt for approximately one week, only healthy animals were subjected to the test. (Preparation of Experimental Animals) Experimental animals: oxaliplatin (hereinafter also referred to as OXP)-induced peripheral neuropathy model mice were prepared using the following method. Grouping was performed based on the pain score evaluated the day before the start of the test (the day before administration of the test substance), specifically, by assigning animals to each group so that the pain score was averaged. Three groups were composed: Group 1: Sham group, Group 2: Control group, and Group 3: Alkalizing agent group. For 17 days from the day after grouping, the Sham and Control groups were orally administered with water for injection, and the Alkalizing agent group was orally administered with 1 g / kg of Uralit twice daily (by oral gavage). Note that administration was performed once daily on the final day of administration, with a 16.5-day dose administered over 17 days. Experimental animals were prepared by a single intraperitoneal administration of 3 mg / kg of OXP on the third day after administration of water for injection or Uralit. The required amount of OXP was weighed and dissolved in glucose injection (5%, Otsuka Pharmaceutical Factory, Inc.) to a concentration of 0.3 mg / mL. The OXP was prepared immediately before use. The sham group received glucose injection (5%) instead of OXP, which was its administration vehicle. (Measurement Time Points) Pain assessment was performed over time after OXP administration. Pain assessment included evaluation of mechanical allodynia and cold dysesthesias. The first day of OXP administration was counted as day 0, and pain assessments were performed 2 hours after administration of water for injection or Uralit on days 0, 1, 3, 6, 8, 10, and 14.Pain assessment was performed the day before the start of Uralyt administration and used as the pre-score. (Pain Assessment) Pain assessment was performed after transferring the animals to individual cages (W 110 × D 180 × H 150 mm) with a mesh bottom for pain scoring and allowing them to acclimate to the new environment for 30 minutes. To assess mechanical allodynia, the plantar surface of the hind paw was stimulated with a Von Frey hair (0.69 mN) and the reactivity to the stimulation was scored. To assess cold dysesthesias (OXP model only), acetone was applied to the plantar skin of the hind paw and the aversive response following the acetone stimulation was scored. (Scoring Method) (1) Mechanical Allodynia: A Von Frey hair was pressed perpendicularly against the center of the plantar surface of the hind paw and held for 1–3 seconds at a position where the filament was slightly bent. Stimuli of the same intensity were applied alternately to each hind paw three times, with a few seconds between each application. The average of all six stimulations (maximum score: 2) was used as the score. 0: No response or hind paw shifting to the side 1: Hind paw lifting 2: Hind paw flinching or licking at the stimulation site (2) Cold dysestesia Acetone was applied to the skin of the plantar hind paw, and the hind paw response was observed for 10 seconds following the reaction immediately after application (not scored). Acetone was applied alternately to each hind paw three times with an interval of at least 20 seconds between applications, and the average of all six applications was used as a score (maximum score is 2). 0: No response or hind paw shifting to the side 1: Hind paw lifting 2: Hind paw flinching or licking at the stimulation site (Results) In OXP-induced peripheral neuropathy model mice, cold dysestesia peaked on Day 3 and mechanical allodynia peaked on Day 10 (Figure 1). Repeated administration of Uralit-U powder to a mouse model of OXP-induced peripheral neuropathy suppressed the onset of mechanical allodynia and cold dysesthesias (Figure 2). Based on the above, repeated oral administration of Uralit-U powder is considered to be highly effective against OXP-induced peripheral neuropathy.
[0098] Example 2: Evaluation of Alkalizing Agents in a Paclitaxel-Induced Mouse Neuropathic Pain Model (Test Substance) The same test substance as in Example 1 was used. (Animals) The same animals as in Example 1 were used. Specifically, 6-week-old male C57BL / 6J mice (Japan SLC) were used. After an approximately one-week acclimatization period, only healthy animals were subjected to the test. (Preparation of Experimental Animals) Experimental animals: paclitaxel-induced peripheral neuropathy model mice were prepared by a single intraperitoneal administration of 5 mg / kg of PTX in the same manner as in Example 1, except that the chemotherapeutic agent inducing peripheral neuropathy was paclitaxel (hereinafter also referred to as PTX) and pain evaluation was performed up to 18 days after PTX administration. The required amount of PTX was weighed and dissolved in the following administration medium to a concentration of 0.5 mg / mL, and the resulting solution was prepared immediately before use. The administration vehicle was prepared freshly by adding 10% (v / v) Kolliphor and ethanol to physiological saline. (Measurement Time Points) Pain assessment was performed over time after PTX administration. Mechanical allodynia was assessed. The first day of PTX administration was counted as day 0, and pain assessments were performed 2 hours after administration of water for injection or Uralit on days 0, 1, 3, 5, 7, 10, 12, 14, and 18 of administration. Pain assessments were performed the day before the start of Uralit administration and used as the pre-value. (Pain Assessment) Pain assessment was performed using the same method as in Example 1. (Results) Mechanical allodynia peaked on day 14 in PTX-induced peripheral neuropathy model mice (Figure 3). Repeated administration of Uralit to PTX-induced peripheral neuropathy model mice suppressed the onset of mechanical allodynia (Figure 4). From the above, it is believed that repeated oral administration of Uralit is highly effective against PTX-induced peripheral neuropathy.
[0099] Example 3: Evaluation of Alkalizing Agents in a Bordezomib-Induced Mouse Neuropathic Pain Model (Test Substance) The same test substance as in Example 1 was used. (Animals) The same animals as in Example 1 were used. Specifically, 6-week-old male C57BL / 6J mice (Japan SLC) were used. After an approximately one-week acclimatization period, only healthy animals were subjected to the test. (Preparation of Experimental Animals) Experimental animals: Bordezomib-induced peripheral neuropathy model mice were prepared by a single intravenous administration of 0.3 mg / kg of BTZ using the same method as in Example 1, except that the chemotherapeutic agent inducing peripheral neuropathy was bordezomib (hereinafter also referred to as BTZ) and pain assessment was conducted up to 15 days after BTZ administration. The required amount of BTZ was weighed and dissolved in physiological saline to a concentration of 0.6 mg / mL, and the solution was prepared immediately before use. (Measurement Time Points) Pain assessment was performed over time after BTZ administration. Pain assessment was performed by evaluating mechanical allodynia. The first day of BTZ administration was counted as day 0, and pain assessment was performed 2 hours after administration of injectable water or Uralit on days 0, 3, 6, 9, 12, and 15 of administration. Pain assessment was performed the day before the start of Uralit administration and used as the pre-value. (Pain Assessment) Pain was assessed using the same method as in Example 1. (Results) In BTZ-induced peripheral neuropathy model mice, the onset of mechanical allodynia was observed, peaking on day 12 (Figure 5). Repeated administration of Uralit to BTZ-induced peripheral neuropathy model mice suppressed the onset of mechanical allodynia (Figure 6). From the above, it is believed that repeated oral administration of Uralit is highly effective against BTZ-induced peripheral neuropathy.
[0100] Example 4: Evaluation of Alkalizing Agents in a Vincristine-Induced Mouse Neuropathic Pain Model (Test Substance) The same test substance as in Example 1 was used. (Animals) The same animals as in Example 1 were used. Specifically, 6-week-old male C57BL / 6J mice (Japan SLC) were used. After an approximately one-week acclimation period, only healthy animals were subjected to the test. (Preparation of Experimental Animals) Experimental animals: vincristine-induced peripheral neuropathy model mice were prepared by a single intraperitoneal administration of 0.1 mg / kg VCN using the same method as in Example 1, except that the chemotherapeutic agent inducing peripheral neuropathy was vincristine (hereinafter also referred to as VCN) and pain assessment was conducted up to 18 days after VCN administration. The required amount of VCN was weighed and dissolved in physiological saline to a concentration of 0.01 mg / mL, and the solution was prepared immediately before use. (Measurement Time Points) Pain assessment was performed over time after VCN administration. Pain assessment was performed by evaluating mechanical allodynia. The first day of VCN administration was counted as day 0, and pain assessments were performed 2 hours after administration of injectable water or Uralit on days 0, 3, 7, 10, 14, and 18 of administration. Pain assessment was performed the day before the start of Uralit administration and used as the pre-value. (Pain Assessment) Pain was assessed using the same method as in Example 1. (Results) In VCN-induced peripheral neuropathy model mice, the onset of mechanical allodynia was observed, peaking on day 14 (Figure 7). Repeated administration of Uralit to VCN-induced peripheral neuropathy model mice suppressed the onset of mechanical allodynia (Figure 8). From the above, it is believed that repeated oral administration of Uralit is highly effective against VCN-induced peripheral neuropathy.
[0101] Example 5: Evaluation of Alkalizing Agents in a Paclitaxel-Induced Rat Neuropathic Pain Model (Test Substance) The same test substance as in Example 1 was used. (Animals) Seven-week-old male SD rats (Jackson Laboratory Japan) were used. After an approximately one-week acclimatization period, only healthy animals were subjected to the test. (Preparation of Experimental Animals) Experimental animals: PTX-induced peripheral neuropathy model rats were prepared using the following method. Grouping was performed based on the 50% withdrawal threshold evaluated the day before the start of the test (the day before administration of the test substance), specifically, by assigning animals to each group so that the 50% withdrawal threshold and body weight were averaged. Three groups were composed: Group 1: Sham group, Group 2: Control group, and Group 3: Alkalizing agent group. For 24 days from the day after grouping, the Sham and Control groups received injectable water, and the Alkalizing agent group received 1 g / kg of Uralit twice daily orally (by oral gavage). The final day of administration was once daily, with a 23.5-day dose administered over 24 days. Experimental animals were prepared by intraperitoneally administering 2 mg / kg of PTX four times every other day (on days 3, 5, 7, and 9 after the start of administration of injectable water or Uralit) beginning on day 3 of administration of injectable water or Uralit. PTX was prepared fresh by adding saline to 30 mg of taxol injection solution to a concentration of 2 mg / mL. The sham group received saline instead of PTX. (Measurement Time Points) Pain assessment was performed over time after PTX administration. Mechanical allodynia was assessed for pain. The first day of PTX administration was counted as day 0, and pain assessments were performed 3 hours after administration of injectable water or Uralit on days 7, 14, and 21 of administration. Pain assessment was performed the day before the start of Uralit administration (Day 3), and this was used as the "Pre" value. (Pain Assessment) Pain assessment was performed by pressing a von Frey filament vertically against the center of the rat's left hind paw, observing the avoidance response, and calculating the 50% withdrawal threshold according to the up-down method of Chaplan et al. (J. Neurosci. Methods. 1994; 53:55-63). (Results) In the PTX-induced peripheral neuropathy model rats, the onset of mechanical allodynia was observed, peaking on Day 21 (Figure 9).Repeated administration of Uralit to rats with PTX-induced peripheral neuropathy suppressed the onset of mechanical allodynia (Figure 9). Based on the above, repeated oral administration of Uralit is considered to be highly effective against peripheral neuropathy induced by repeated administration of PTX.
[0102] Example 6: Evaluation of Alkalizing Agents in a Paclitaxel-Induced Mouse Neuropathic Pain Model. This example examined the effects of administering an alkalizing agent to a paclitaxel-induced neuropathic pain model on spontaneous and mechanical stimulation-induced firing of spinal dorsal horn neurons. (Test Substance) The same test substance as in Example 1 was used. (Animals) The same animals as in Example 1 were used. Specifically, 6-week-old male C57BL / 6J mice (Japan SLC) were used. After an approximately one-week acclimation period, only healthy animals were used in the study. (Experimental Animal Preparation) Experimental animals: paclitaxel-induced peripheral neuropathy model mice were prepared by a single intraperitoneal administration of 5 mg / kg of PTX using the same method as in Example 1, except that the chemotherapeutic agent inducing peripheral neuropathy was paclitaxel and pain assessment was performed up to 14 days after PTX administration. The required amount of PTX was weighed and dissolved in the following administration vehicle to a concentration of 0.5 mg / mL, and prepared immediately before use. The administration vehicle was prepared by adding Kolliphor and ethanol to physiological saline to a concentration of 10% (v / v). (Evaluation) (1) Pain Evaluation by Mechanical Allodynia (Measurement Time Points) 3 days before and 13 days after PTX administration. (Pain Evaluation) Pain evaluation by mechanical allodynia was performed using the same method as in Example 1. (Scoring Method) Scoring was performed using the same method as in Example 1. (Results) In PTX-induced peripheral neuropathy model mice, the onset of mechanical allodynia was observed on Day 13, but repeated administration of uralit suppressed the onset of mechanical allodynia (Figure 10). (2) Electrophysiological Analysis (Preparation of Animals for Electrophysiological Experiments) 14 days after PTX administration, mice were deeply anesthetized with urethane (1.2-1.5 g / kg, i.p.), laminectomized at the thoracic and lumbar spinal cord level, and placed in a stereotaxic apparatus. The dura, arachnoid, and pia mater were sequentially peeled away under a stereomicroscope to expose the dorsal roots and secure space for electrode insertion. Krebs solution, saturated with 95% oxygen and 5% carbon dioxide and heated to 37°C, was then perfused over the spinal cord surface at a rate of 10-15 mL / min.Next, a tungsten electrode (FHC) was inserted into the superficial layer of the spinal dorsal horn (10-150 μm (Laminae I-II)) at the L4-L5 input site, and recording was performed. (Measurement Time Point) Measurements were performed on the prepared electrophysiological experimental animals at two points: before and after stimulation with the Von Frey Hair. (Electrophysiological Evaluation) Signals obtained from the measurements were amplified using an EX1 (Dagan Corporation), converted to digital data using a Digidata 1400A (Molecular Devices, LLC.), and recorded using the software Clampex ver. 10.2 (Molecular Devices, LLC.). Analysis was performed using the software Clampfit ver. 10.2 (Molecular Devices, LLC.). Firing was recorded without stimulation of the mice, and the frequency of spontaneous firing per unit time was evaluated. Subsequently, single neurons were identified using a paintbrush and hooked tweezers, and the receptive fields were also identified. A 0.69 mN von Frey filament (vFF) was applied to this area for 5 seconds, and the evoked firing was recorded as mechanical stimulation-induced firing, and the occurrence frequency per unit time was evaluated. (Results) Repeated administration of Uralit suppressed both the increase in spontaneous firing frequency and vFF-induced firing frequency observed in the spinal dorsal horn of PTX-induced peripheral neuropathy model mice (Figures 11 and 12). These results suggest that repeated oral administration of Uralit is highly effective against PTX-induced peripheral neuropathy.
[0103] Example 7: Evaluation of an Alkalizing Agent in an Oxaliplatin-Induced Mouse Neuropathic Pain Model (Test Substance) The alkalinizing agent used was the test substance used in Example 1, and sodium bicarbonate (also referred to herein as baking soda; manufactured by Tokyo Chemical Industry Co., Ltd.; purity: 99.0% or higher). The required amount of sodium bicarbonate was weighed and dissolved in water for injection to achieve the desired concentration, preparing the solution immediately before use. Water for injection, the solvent for the alkalinizing agent, was used in the sham and control groups. (Animals) The same animals as in Example 1 were used. Specifically, 6-week-old male C57BL / 6J mice (Japan SLC) were used. After an acclimatization period of approximately one week, only healthy animals were subjected to the study. (Preparation of Experimental Animals) Experimental animals: mice with an oxaliplatin-induced peripheral neuropathy model were prepared using the following method. The subjects were divided into groups based on the pain score evaluated on the day before the start of the study (the day before administration of the test substance), specifically, by allocating the subjects to each group so that the pain score was averaged. The four groups were: Group 1: Sham group, Group 2: Control group, Group 3: Alkalizing agent (Uralyt) group, and Group 4: Alkalizing agent (sodium bicarbonate) group. For 13 days from the day after grouping, the Sham and Control groups received injectable water, while the Alkalizing agent (Uralyt) group received 1 g / kg of Uralyt, and the Alkalizing agent (sodium bicarbonate) group received 0.75 g / kg of sodium bicarbonate, each administered orally twice daily (by oral gavage). The final day of administration was once daily, with a 12.5-day dose administered over 13 days. Experimental animals were prepared by a single intraperitoneal administration of 3 mg / kg of OXP on the third day after administration of water for injection, uralyt, or sodium bicarbonate. The required amount of OXP was weighed and dissolved in glucose injection (5%, Otsuka Pharmaceutical Factory, Inc.) to a concentration of 0.3 mg / mL, and prepared immediately before use. The sham group received the administration vehicle, glucose injection (5%), instead of OXP. (Measurement Time Points) Pain assessment was performed over time after OXP administration. Mechanical allodynia was assessed for pain. The first day of OXP administration was counted as day 0, and pain assessments were performed 2 hours after administration of water for injection, uralyt, or sodium bicarbonate on days 0, 3, 5, 7, and 10.Pain assessment was performed the day before the start of alkalizing agent administration and used as the "Pre" value. (Pain Assessment) Mechanical allodynia was assessed using the same method as in Example 1. (Results) In OXP-induced peripheral neuropathy model mice, the onset of mechanical allodynia was observed, peaking on Day 10 (Figure 13). Repeated administration of Uralit U powder to OXP-induced peripheral neuropathy model mice inhibited the onset of mechanical allodynia (Figure 14). Repeated administration of sodium bicarbonate to OXP-induced peripheral neuropathy model mice inhibited the onset of mechanical allodynia, but the effect was smaller than in the Uralit-administered group (Figure 14). From the above, it is believed that repeated oral administration of alkalizing agents (especially Uralit) is highly effective against OXP-induced peripheral neuropathy.
[0104] Example 8: Evaluation of an Alkalizing Agent in a Paclitaxel-Induced Mouse Neuropathic Pain Model (Test Substance) The alkalizing agent used was the test substance used in Example 1, and sodium bicarbonate (also referred to herein as baking soda; manufactured by Tokyo Chemical Industry Co., Ltd.; purity: 99.0% or higher). The required amount of sodium bicarbonate was weighed and dissolved in water for injection to achieve the desired concentration, preparing the solution immediately before use. Water for injection, a solvent for the alkalizing agent, was used in the sham and control groups. (Animals) The same animals as in Example 1 were used. Specifically, 6-week-old male C57BL / 6J mice (Japan SLC) were used. After an acclimatization period of approximately one week, only healthy animals were used in the study. (Preparation of Experimental Animals) Experimental animals: mice with a paclitaxel-induced peripheral neuropathy model were prepared using the following method. The subjects were divided into groups based on the pain score evaluated on the day before the start of the study (the day before administration of the test substance), specifically, by allocating the subjects to each group so that the pain score was averaged. The four groups were: Group 1: Sham group, Group 2: Control group, Group 3: Alkalizing agent (Uralyt) group, and Group 4: Alkalizing agent (sodium bicarbonate) group. For 17 days from the day after grouping, the Sham and Control groups received injectable water, while the Alkalizing agent (Uralyt) group received 1 g / kg of Uralyt and the Alkalizing agent (sodium bicarbonate) group received 0.75 g / kg of sodium bicarbonate, each administered orally twice daily (by oral gavage). The final day of administration was once daily, with a 16.5-day dose administered over 17 days. Experimental animals: Paclitaxel-induced peripheral neuropathy model mice were prepared by a single intraperitoneal administration of 5 mg / kg of PTX on the third day after administration of water for injection, uralyt, or sodium bicarbonate. The required amount of PTX was weighed and dissolved in the following administration medium to a concentration of 0.5 mg / mL, and prepared immediately before use. The administration medium was prepared immediately after use by adding Kolliphor and ethanol to physiological saline to make 10% (v / v) concentrations. (Measurement Time Points) Pain was assessed over time after PTX administration. Mechanical allodynia was assessed for pain.The first day of PTX administration was counted as day 0, and pain assessments were performed 2 hours after administration of injectable water, ularit, or sodium bicarbonate on days 0, 1, 3, 5, 7, 10, 12, and 14. Pain assessment was performed the day before the start of alkalinizing agent administration and used as the "Pre" value. (Pain Assessment) Pain assessment for mechanical allodynia was performed using the same method as in Example 1. (Results) In PTX-induced peripheral neuropathy model mice, mechanical allodynia peaked on day 14 ( FIG. 15 ). Repeated administration of ularit to PTX-induced peripheral neuropathy model mice suppressed the onset of mechanical allodynia ( FIG. 16 ). Repeated administration of sodium bicarbonate to PTX-induced peripheral neuropathy model mice suppressed the onset of mechanical allodynia, but the effect was smaller than in the ularit-treated group ( FIG. 16 ). From the above, it is believed that repeated oral administration of alkalizing agents (especially Uralit) is very effective against PTX-induced peripheral neuropathy.
[0105] The pharmaceutical composition, combined preparation, and pharmaceutical kit provided by the present invention enable the treatment or prevention of peripheral neuropathy induced by a chemotherapeutic agent, and also enable the treatment of cancer by suppressing peripheral neuropathy induced by a chemotherapeutic agent, particularly a cancer chemotherapeutic agent.
Claims
1. A pharmaceutical composition for treating or preventing peripheral neuropathy induced by a chemotherapy agent, comprising an alkalizing agent.
2. The pharmaceutical composition according to claim 1, wherein the peripheral neuropathy induced by a chemotherapy drug is pain, sensory disorder, motor disorder, autonomic neuropathy, or a complication thereof caused by peripheral neuropathy.
3. The pharmaceutical composition according to claim 1 or 2, wherein the peripheral neuropathy induced by a chemotherapy drug is peripheral neuropathic pain.
4. The pharmaceutical composition according to claim 3, wherein the peripheral neuropathic pain is electric shock pain, burning pain, pain (excluding electric shock pain and burning pain), or tingling sensation.
5. The pharmaceutical composition according to claim 1 or 2, wherein the peripheral neuropathy induced by a chemotherapy drug is a sensory disturbance caused by peripheral neuropathy.
6. The pharmaceutical composition according to claim 5, wherein the sensory disturbance caused by peripheral neuropathy is hypoesthesia, hyperesthesia or dysesthesia.
7. The pharmaceutical composition according to claim 6, wherein the hyperesthesia is allodynia and the paresthesia is dysesthesia or paresthesia.
8. The pharmaceutical composition according to claim 1 or 2, wherein the peripheral neuropathy induced by a chemotherapy drug is an autonomic neuropathy caused by peripheral neuropathy.
9. The pharmaceutical composition according to claim 8, wherein the symptoms caused by autonomic nervous system disorders are dysuria, abnormal sweating, orthostatic hypotension, constipation, or paralytic ileus.
10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the peripheral neuropathy induced by a chemotherapy drug is peripheral neuropathy in which symptoms appear in the limbs.
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the alkalizing agent is a pharma- ceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof.
12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the alkalizing agent is sodium citrate, potassium citrate or a hydrate thereof, or a mixture thereof.
13. The pharmaceutical composition of any one of claims 1 to 12, wherein the alkalinizing agent comprises a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof.
14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the alkalizing agent is sodium citrate or a hydrate thereof.
15. The pharmaceutical composition according to any one of claims 1 to 14, wherein the pharmaceutical composition is a tablet.
16. The pharmaceutical composition of any one of claims 1 to 10, wherein the alkalizing agent is sodium bicarbonate.
17. The pharmaceutical composition according to any one of claims 1 to 16, wherein the chemotherapeutic agent is a cancer chemotherapeutic agent.
18. The pharmaceutical composition according to claim 17, wherein the cancer chemotherapeutic drug is a cytotoxic anticancer drug, a molecular targeted anticancer drug, an immunotherapeutic drug, or other anticancer drug.
19. The pharmaceutical composition of claim 18, wherein the cytocidal anticancer drug is at least one anticancer drug selected from the group consisting of paclitaxel, docetaxel, cabazitaxel, vinorelbine, vincristine, vinblastine, vindesine, eribulin, oxaliplatin, carboplatin, cisplatin, and nelarabine.
20. The pharmaceutical composition according to claim 18, wherein the molecular targeted anticancer drug is at least one anticancer drug selected from the group consisting of bortezomib, ixazomib, romidepsin, gilteritinib, trastuzumab emtansine, brentuximab vedotin, obinutuzumab, blinatumomab, lorlatinib, entrectinib, encorafenib, binimetinib, and pemigatinib.
21. The pharmaceutical composition of claim 18, wherein the immunotherapeutic agent is at least one anticancer agent selected from the group consisting of nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab.
22. The pharmaceutical composition according to claim 18, wherein the other anticancer drug is at least one anticancer drug selected from the group consisting of cytarabine, ifosfamide, nedaplatin, thalidomide, lenalidomide and pomalidomide.
23. The pharmaceutical composition of claim 17, wherein the cancer chemotherapy drug is at least one anticancer drug selected from the group consisting of paclitaxel, vincristine, oxaliplatin and bortezomib.
24. The pharmaceutical composition of claim 23, wherein the cancer chemotherapy drug is paclitaxel or oxaliplatin.
25. A combination preparation for simultaneous, separate or sequential administration in the treatment of cancer, said combination preparation comprising at least two separate formulations of an alkalizing agent and a cancer chemotherapeutic agent, wherein the occurrence of peripheral neuropathy is suppressed.
26. An anti-cancer pharmaceutical composition comprising an alkalizing agent and a cancer chemotherapeutic drug, which suppresses the onset of peripheral neuropathy.
27. An anti-cancer pharmaceutical kit, which comprises an alkalizing agent in a first compartment and a cancer chemotherapeutic drug in a second compartment, and which suppresses the onset of peripheral neuropathy.
